Molecular Mechanisms of Vascular Health:
Insights From Vascular Aging and Calcification

Nadia R. Sutton , Rajeev Malhotra , Cynthia St. Hilaire, Elena Aikaw , Roger S. Blumenthal , Grace Gackenbach, Parag Goyal , Adam Johnson, Sagar U. Nigwekar, Catherine M. Shanahan, Dwight A. Towler , Brooke N. Wolford, Yabing Chen

ABSTRACT: Cardiovascular disease is the most common cause of death worldwide, especially beyond the age of 65 years, with the vast majority of morbidity and mortality due to myocardial infarction and stroke. Vascular pathology stems from a combination of genetic risk, environmental factors, and the biologic changes associated with aging. The pathogenesis underlying the development of vascular aging, and vascular calcification with aging, in particular, is still not fully understood. Accumulating data suggests that genetic risk, likely compounded by epigenetic modifications, environmental factors, including diabetes and chronic kidney disease, and the plasticity of vascular smooth muscle cells to acquire an osteogenic phenotype are major determinants of age-associated vascular calcification. Understanding the molecular mechanisms underlying genetic and modifiable risk factors in regulating age-associated vascular pathology may inspire strategies to promote healthy vascular aging. This article summarizes current knowledge of concepts and mechanisms of age-associated vascular disease, with an emphasis on vascular calcification.

Highlights

- The pathogenesis underlying the development of vascular aging, and vascular calcification with aging, in particular, is still not fully understood.
- Genetic risk, likely compounded by epigenetic modifications, environmental factors, including diabetes mellitus and chronic kidney disease, and the plasticity of vascular smooth muscle cells to acquire an osteogenic phenotype are major determinants of age-associated vascular calcification.
- Arterial smooth muscle cell phenotypic switching contributes significantly to vascular aging—manifested as abnormal conduit vessel physiology and mechanical integrity due to arteriosclerotic calcification, fibrosis, matrix remodeling, and impaired contractile functions.

Cardiovascular disease is the leading cause of death worldwide and increases with age, in large part due to the cumulative effects of risk factors, such as hypertension, hyperlipidemia, diabetes, tobacco use, and sedentary behavior. However, with advancing age, even individuals without traditional risk factors gradually develop vascular pathology including arterial fibrosis, stiffness, and calcification, increasing the risk of serious cardiovascular events. The importance of understanding the interplay between vascular biology and aging, independent of traditional risk factors, is of utmost importance.

Isolating vascular aging as an independent biological variable is challenging for several reasons. First, vascular aging is often accompanied by one or more cardiovascular

disease risk factors. Second, there is likely a synergistic effect of both the duration and number of cardiovascular risk factors that make it challenging to fully adjust for such variables. Although studies of aging exist, they are prone to survival bias in that only individuals who survived until older age can be studied if not enrolled earlier in life. Studies, such as the PESA (Progression and Early Detection of Subclinical Atherosclerosis)[1] and the Asklepios Study,[2] were designed to circumnavigate these challenges to study the interactions of age and inflammation with cardiovascular hemodynamics and development of atherosclerosis. Studies of human longevity are also challenging due to the costly and time-consuming nature of studying an individual human over a lifespan, and long-lived individuals may have different genetic longevity variants and protein signatures.[3–5]

Improving our understanding of vascular aging and its role in cardiovascular disease progression, morbidity, and mortality is essential. The following review discusses what is currently known regarding the biology of vascular aging, clinical manifestations of age-associated vascular disease with a focus on calcification, the impact of genetic risk on vascular aging, and the environmental and molecular factors that may influence vascular aging and promote longevity (Figure).

Clinical Manifestations of Age-Associated Cardiovascular Calcification

Arterial stiffening and calcification are characteristics of vascular aging, serve as important predictors of cardiovascular morbidity and mortality, and are exacerbated by cardiovascular disease risk factors and metabolic syndromes.[6–9] Arterial calcification is closely associated with atherosclerotic plaque evolution, and the area of coronary artery calcification (CAC) quantified on noncontrast cardiac computed tomography has a direct relationship with histopathologic coronary plaque area.[10] Autopsy studies have consistently shown a strong association between calcification of the coronary arteries and atherosclerosis.[11] Calcification is often categorized as intimal, typically associated with atherosclerotic plaque, or medial, often a more diffuse arteriosclerotic process marked by vascular stiffening and associated with conditions such as chronic kidney disease (CKD) and diabetes.

CAC volume and vulnerable plaques with a lipid-rich core, thin cap, or spotty or micro calcifications are associated with the risk of future atherosclerotic cardiovascular disease (ASCVD) events.[12–15] However, within a given coronary artery, there is a wide variation between the degree of plaque calcification and severity of luminal stenosis on invasive coronary angiography due in part to individual variations in coronary artery remodeling.[16]

Noninvasive methods to evaluate coronary heart disease risk, such as exercise stress testing, typically only identify patients with advanced, obstructive atherosclerotic disease. This is of relevance as myocardial infarctions may occur when a nonobstructive atherosclerotic plaque ruptures.[17] Thus, there has been great interest in characterizing atherosclerosis in its pre-flow limiting phase so that intensified preventive strategies can be instituted. Measurement of CAC volume on computed tomography imaging often improves the accuracy of cardiovascular risk assessment in intermediate-

risk adults and may help to determine which patients may benefit from initiation of or intensification of risk factor modification strategies such as lipid-lowering, aspirin, or antihypertensive therapies.[18–20]

Prospective studies of CAC and incident cardiovascular disease risk from the Multi-Ethnic Study of Atherosclerosis and other observational cohorts show a very strong correlation between increased CAC and the risk of future cardiovascular disease events.[21] CAC scores greater than the 75th percentile for age, sex, and ethnicity or more than 100 indicate an elevated 10-year ASCVD risk and should lead to more improved lifestyle habits and strong consideration of statin therapy in intermediate-risk adults.[20] CAC percentiles based on age, sex, and ethnicity are better predictors of lifetime risk, whereas CAC scores provide the best estimate of absolute risk in the next decade.[19]

Traditionally, CAC scores have been used to determine the need for initiating statin therapy. However, evidence suggests that while high-intensity statin therapy lowers cardiovascular event risk, it paradoxically may modestly increase CAC and potentially stabilize existing atherosclerotic plaques.[22,23] Although CAC volume has been associated with increased CVD risk, CAC density is inversely associated with CVD risk.[24] Statin-induced atherosclerotic plaque calcification has been attributed to increased plaque alkaline phosphatase activity[25] and disinhibition of the macrophage Rac (Ras-related C3 botulinum toxin substrate)–IL-1β (interleukin-1 beta) signaling axis.[26]

Emerging data has indicated that CAC scores can help in prioritizing the need for more intensive medications in higher-risk individuals who have above average-amounts of CAC for their age, gender, and ethnicity. These medications may include glucagon-like peptide 1 receptor agonists or SGLT-2 (sodium-glucose cotransporter 2) inhibitors in adults with diabetes or PCSK-9 (proprotein convertasesubtilisin/kexin type 9) inhibitors in adults with suboptimal LDL (low-density lipoprotein)-cholesterol lowering on maximally tolerated statin therapy. Cainzos-Achirica et al[27] have made a compelling case for measuring CAC to more accurately allocate medications and to use the CAC score to enrich study populations of primary prevention randomized controlled trials with participants at higher absolute risk of cardiovascular events. Conversely, a CAC score of zero is a powerful negative predictor of future cardiovascular events in older patients, such that it is reasonable to consider withholding statin therapy in the absence of other risk factors.[28] Additional study of individuals who age without developing vascular calcification would be of interest.

Measurement of CAC is well-validated for risk stratification in middle to older-age adults. Incorporating CAC scores improves risk stratification for incident sudden cardiac death beyond traditional ASCVD risk factors in individuals with low-to-intermediate risk.[29] Until recently, there was limited data in adults with an age <40 years. Javaid et al[30] recently studied the prognostic importance of CAC in nearly 20 000 asymptomatic adults aged 30 to 45 years without known ASCVD. They found that any CAC in this age range

placed females at >90th percentile (high lifetime risk). The presence of any CAC placed White males at the 90th percentile by age 34 years and Black males by age 37 years.

Extracoronary cardiovascular calcification, including aortic,[31] peripheral vascular,[32] and valvular, also predicts cardiovascular risk. Calcific aortic valve stenosis is the most common valvular heart disease in the Western world, and progressive fibrocalcific changes in the valve leaflets may lead to partial aortic outflow tract obstruction.[33] However, aortic valve sclerosis (calcification and thickening of the aortic valve), even in the absence of hemodynamically significant obstruction of left ventricular outflow track, is independently associated with an increased risk of ASCVD events.[34–36] Research is ongoing to determine if aortic valve calcium scoring using cardiac computed tomography may be useful for risk stratification and to identify those at increased risk of developing significant aortic valve stenosis.[37]

A striking demonstration of accelerated vascular calcification in adults is calciphylaxis— a rare but devastating condition that is predominantly seen among patients with end-stage kidney disease who have typically been dialysis-dependent for over 2 to 3 years.[38] The primary clinical manifestation of calciphylaxis is painful skin ulcers caused by cutaneous ischemia. These patients, almost universally, have diffuse extraskeletal calcification. In addition to metabolic abnormalities of calcium and phosphate metabolism originating from the end-stage kidney disease, over 40% of patients with calciphylaxis have diabetes, and as many as 30% have been exposed to warfarin before the development of calciphylaxis.[39,40]

Warfarin, a vitamin K antagonist, may impair the gamma-carboxylation of a potent calcification inhibitor known as MGP (matrix gla protein). This may further accelerate the process of vascular calcification among patients who are predisposed to it from their underlying comorbidities. At present, there is no approved treatment for calciphylaxis, although anecdotal reports of successful resolution of calciphylaxis lesions with treatments such as vitamin K supplementation and kidney transplantation provide potential insights into strategies to reduce calcification and eventually improve clinical outcomes.[41,42]

Biology of Vascular Aging
Vascular aging is a biological variable, conceptually distinct from chronological aging, whereby sequential and progressive changes in a cell or whole organism lead to an increased risk of dysfunction, disease, and death.[43–45] Hallmarks of biological aging include cellular dysfunction and vulnerability to cell death, and many of these hallmarks also contribute to vascular dysfunction and calcification.[46–48]

Telomeres shorten with every cellular replication cycle leading to reduced proliferative capacity of cells.[49,50] The single-strand ends of telomeres are protected to prevent the chromosomal ends from appearing as double-stranded DNA breaks, which otherwise trigger DNA damage responses.[51] Breakdown of these telomere caps can lead to age-related vascular dysfunction, including increased cellular senescence, oxidative stress, and inflammation.[52,53]

Senescent cells are not inert and may extrude chemical mediators that further propagate an inflammatory phenotype to neighboring cells.[54] Vascular smooth muscle cells (SMCs) exhibit markers of senescence and calcify in response to uptake of endothelial-derived exosomes.[55,56] In addition, microparticles from older individuals' senescent endothelial cells induce vascular SMC calcification,[57] and human vascular function in vivo inversely correlates with the presence of senescence markers in endothelial cells.[58] In mice, senolytic drugs, which induce death of senescent cells, restore vascular function in aged mice.[59]

Accumulation of DNA damage, whether due to exogenous factors (such as ionizing radiation), replication errors, or impaired repair, contributes to cellular dysfunction in part due to the generation of reactive oxygen and nitrogen species and may also lead to cardiovascular calcification.[60,61] Increased oxidative stress is also a major factor promoting loss of vascular SMC contractility and increased osteogenic differentiation and calcification, characteristics of vascular aging.[8,62]

Inflammaging, or the age-related increase in proinflammatory markers in the blood and tissues,[63] is likely both a biomarker of biological aging as well as cause of age-related cardiovascular pathology. Inflammaging may occur due to increased production of inflammatory mediators, such as from senescent cells, or due to impaired inflammatory resolution,[64,65] as was recently reviewed in detail elsewhere as a target in atherosclerosis.[66] That endothelial cells stimulated with TNF (tumor necrosis factor) α released microparticles containing BMP2 (bone morphogenetic protein 2), which in turn were phagocytosed by vascular SMCs and enhanced osteogenesis supports the role for inflammaging in promoting age-associated arterial calcification.[67] BMP2 is also proinflammatory and induces endothelial activation, suggesting these local inflammatory perturbations could autofeedback and escalate age-associated calcification.[68] CRP (C-reactive protein) has been implicated in promoting age-associated vascular SMC osteogenic transdifferentiation via the Fc fragment of IgG receptor IIa and the p38 mitogen-activated protein kinase pathway.[69]

Epigenetic marks on histones can dictate global gene expression patterns.[44] These epigenetic modifications correlate with biological age and more accurately predict lifespan than chronological age.[70–72] Epigenetic programming occurs during development and informs cellular phenotypes. Recent studies show that these developmental programs, or the loss of them, help to drive vascular cell dysfunction, including calcification and the loss of the contractile phenotype of vascular SMCs.[73–79]

Genetic Risk and Cardiovascular Disease
While many traditional risk factors become more clinically relevant in middle age, one's genetics are present from birth. Polygenic scores (PGS, also known as genetic risk scores or polygenic risk scores) build on results from genome-wide association studies (GWASs) to allow estimation of one's cumulative genetic risk for a given end point.[80] PGS enable identification of patients at high risk for common, complex diseases, such as cardiovascular disease (CVD), much like carriers of a Mendelian mutation. PGS also allow for improved reclassification of patients with cardiovascular

disease and early onset myocardial infarction and early onset coronary heart disease.[81,82]

For example, in the UK Biobank, participants with a PGS for coronary artery disease in the top 5% of the cohort's PGS distribution have a >3-fold risk for coronary artery disease compared with the rest of the population.[83] This is similar to the coronary artery disease risk conferred by mutations in genes causing familial hypercholesterolemia, yet 20× as many individuals fall into this polygenic high-risk category as carry a familial hypercholesterolemia mutation.[83,84] Moreover, PGS have stronger risk stratification power in younger populations than older ones.[85] PGS have been found to predict incident CAC[86–88] and can be useful in predicting the optimal age for CAC screening.[89] Favorable lifestyles mitigate the susceptibility to CAC even if genetic risk is elevated.[90]

The Finnish GeneRISK study, a web-based communication tool (KardioKompassi), aims to assess the clinical utility of PGS by providing personalized 10-year CVD risk to a prospective cohort of 7342 individuals.[91] After only 1.5 years, 71% of the participants were reassessed, and genetic risk was found to motivate positive health behavior. In another study with a prospective observational cohort of 3800 individuals, knowledge of having a high coronary artery disease PGS was associated with earlier initiation (52 years versus 65 years) and use of a lipid-lowering therapy (42.4% versus 28.5%).[92]

The potential clinical utility of PGS is often quantified with the net reclassification index (NRI), the percent of patients who would be reclassified into a different risk category upon addition of the PGS to conventional CVD risk prediction models (Table 1). An important limitation is that PGSs have mostly been derived from populations of European genetic ancestry and are generally not available at large commercial labs for clinical use. However, the American Heart Association recently issued a scientific statement with guidance for their use.[93]

Genetics Underpinnings of Cardiovascular Calcification
In contrast to the use of polygenic scores based on common genetic variation to predict risk, certain gene defects are responsible for rare, Mendelian disorders of premature vascular pathology (Table 2). For example, rare diseases resulting in premature vascular calcification stem from abnormalities in the extracellular ATP metabolic pathway.[101] ATP is released from cells under conditions of stress or death and can act in a paracrine manner through its cognate receptors or be metabolized to its constituent parts by a series of ectonucleotidases.[102] Several ATP metabolites regulate vascular calcification.[103] Calcium and inorganic phosphate are the building blocks of calcification, but an endogenous inhibitor of mineral nucleation is pyrophosphate, which is the product of the breakdown of ATP by ENPP1 (ectonucleotide pyrophosphatase/phosphodiesterase 1).[103] In a murine model of Hutchinson-Gilford progeria syndrome with accelerated vascular aging, pyrophosphate treatment inhibited arterial calcification.[104]

In generalized arterial calcification of infancy, mutations in *ENPP1* lead to a deadly disease of extensive medial arterial calcification in large arteries, which presents in infancy, and it is the lack of local production of extracellular pyrophosphate that drives this devastating phenotype.[113] The other product of ENPP1 is AMP (adenosine monophosphate), which is further metabolized to inorganic phosphate and adenosine by the ectonucleotidase CD73.[103] Inactivating mutations in the gene encoding for CD73 lead to medial arterial calcifications in adulthood that phenocopy the pathologies seen in patients with diabetes and ESRD.[114,116] In this disease (termed Arterial Calcification due to Deficiency of CD73), mechanistic studies have uncovered that the lack of adenosine signaling via the A2bAR (A2b adenosine receptor) drives the osteogenic transition of these SMCs.[117] Calcified femoropopliteal arteries from patients with non-genetic forms of medial arterial calcification exhibit signatures of this rare disease, suggesting the mechanism that operates in this pathology.[118,119] Pseudoxanthoma elasticum is characterized by microvascular arterial calcification in childhood and is caused by mutations in the ATP binding cassette subfamily C member 6 (*ABCC6*); however, the factor being transported is debated.[115,120] Singleton-Merton syndrome is caused by a missense mutation in interferon-induced helicase C domain 1 (*IFIH1*),[121] and Hutchinson-Gilford progeria syndrome is caused by a splice defect in lamin A (*LMNA*)[122,123]; both disorders manifest with premature and extensive aortic and valvular calcification. The relationships of these genes to adult, age-related calcific disorders, however, remain uncertain.

GWAS have identified several seemingly unrelated genes implicated in CAC. The first GWAS for CAC identified two loci at 6p24 and 9p21.[105] The former is nearest to the phosphatase and actin regulator 1 (*PHACTR1*) gene, which plays a role in endothelial cell survival. Targeted deletion at this locus increases the expression of nearby gene endothelin 1 (*EDN1*), a potent vasoconstrictor known to promote atherosclerosis.[106] In an exome-wide association meta-analysis, protein-coding variants in *APOB* and *APOE* were also associated with CAC among patients without overt coronary heart disease, thus linking CAC, perhaps unsurprisingly, with lipid metabolism.[107]

More recently identified is the association between clonal hematopoiesis of indeterminate potential with CAC. Clonal hematopoiesis of indeterminate potential carriers had 3.3 times higher CAC than noncarriers.[124] Insufficiency of tet methylcytosine dioxygenase 2 (*TET2*), a gene commonly mutated in clonal hematopoiesis of indeterminate potential, exaggerated atherosclerosis in mice,[124] which has been attributed to TET-2–deficient macrophages exhibiting an increase in

NLRP (nucleotide-binding oligomerization domain, leucine-rich repeat and pyrin domain containing) 3 inflammasome-mediated IL-1β secretion.[125] Finally, *MGP* is considered to be one of the strongest endogenous inhibitors of vascular calcification, and putatively disruptive polymorphisms in *MGP* correlate strongly with subclinical CAC.[126] These findings highlight the diversity of known cell types (eg, endothelial, SMC, hematopoietic) and signaling pathways involved in CAC development.

GWAS have also identified an abdominal aortic calcification risk locus on chromosome 7 in the intergenic region between histone deacetylase 9 (*HDAC9*) and twist family bHLH (basic helix-loop-helix) transcription factor 1 (*TWIST1*).[108] Knockdown of *HDAC9* reduced calcification, contractility, and *RUNX2* expression of aortic SMCs induced to undergo osteogenic transformation.[108] Conversely, overexpression of *HDAC9* amplified *RUNX2* expression and increased calcification.[108] Analogously, *Hdac9*-null mice were protected from calcification and mortality compared to haploinsufficient and wild-type mice in a model of medial vascular calcification (MGP deficiency).[108] HDAC9 also promotes endothelial-to-mesenchymal transition and unfavorable atherosclerotic plaque composition.[109] In rat SMC calcification assays, *TWIST1* knockdown increased calcification, and overexpression decreased calcification.[110]

Aortic valvular calcification has been associated with the lipoprotein a (*LPA*) locus on chromosome 6 at genome-wide significance, and minor alleles in this locus confer as much as a 2-fold increase in the odds of aortic valvular calcification and an increased risk for aortic stenosis.[111] Mendelian randomization analysis demonstrated a causal role for genetically determined Lp(a) (lipoprotein [a]) levels in the development of aortic valvular calcification. In the same study, two variants near the proinflammatory gene, interleukin 36 gamma (*IL1F9*), were associated with mitral annular calcification at a genome-wide level of significance.

In a separate GWAS of calcific aortic stenosis, the association of aortic valvular disease with *LPA* was redemonstrated, and 2 additional risk loci near palmdelphin (*PALMD*) and testis expressed 41 (*TEX41*) were identified.[112] These loci are also associated with bicuspid aortic valve and congenital septal defects, potentially implicating cardiac developmental pathways in calcific aortic valve disease.

Environmental and Modifiable Factors That Accelerate Calcification
There are several clinical conditions where vascular calcification is markedly accelerated, including metabolic abnormalities, such as diabetes and CKD.[127] In these conditions, calcification, and mortality do not track with chronological age, as observed in the general population. Instead, patients show accelerated cardiovascular mortality, such that young adults with end-stage kidney disease requiring chronic dialysis have a risk of cardiovascular mortality similar to octogenarians.[128,129] Emerging evidence suggests that accelerated vascular aging may contribute to the development of vascular calcification and increased mortality in these patient groups.[130–133]

Using human tissue samples, several studies have documented the presence of DNA damage (gH2AX [gamma H2 histone family member X] and 8-oxo-Dg [8-oxo-2'-deoxyguanosine]) and senescence markers, such as the cell cycle regulators p21 and p16, in calcified arteries of patients with CKD and diabetes.[133] Compelling evidence comes from studies of the arteries of children with CKD on dialysis, which showed elevated oxidative DNA damage and senescence in medial vascular SMCs.[131] Numerous ex vivo and in vitro studies of SMCs have shown that several environmental factors contribute to oxidative stress and DNA damage in these disease

states. These include elevated glucose and dysregulated mineral metabolism, with elevated phosphorus thought to be a driver of premature aging, as well as various uremic toxins and mitochondrial damage.[127,134–138]

DNA damage signaling and cellular senescence drive several processes that lead to vascular SMC calcification, including osteogenic differentiation and cell death. Two key DNA damage signaling pathways upstream of vascular SMC osteogenic differentiation are ataxia telangiectasia mutated and PARP (poly-ADP ribose polymerase), and blocking either of these pathways can alleviate mineralization both in vitro and in vivo in models that mimic the dysregulated mineral metabolism observed in CKD.[77,139]

These signaling pathways exert their effects on osteogenic differentiation of SMCs in several ways, and many of them converge to the Runx2 (runt-related transcription factor-2), the major transcription factor driving osteogenic phenotype transition.[140–146] Oxidative stress-induced Runx2 upregulation plays an essential role in vascular SMC calcification, while SMC-specific Runx2 deletion protects from the development of vascular calcification in atherosclerosis and CKD.[144–146] Multifaceted posttranslational modifications of Runx2, including phosphorylation, acetylation, ubiquitination, and O-GlcNAcylation (O-linked-N-acetylglucosaminylation), modulate Runx2 protein stability, cellular localization, and its interaction with other transcription factors and target genes that are critical for its osteogenic transcriptional activity.[138]

Recent studies have linked protein O-GlcNAcylation with Runx2 upregulation and SMC calcification in diabetes.[147–150] In addition, Runx2 is a component of the DNA damage response. In response to elevated calcium and phosphate, Runx2 becomes poly-ADP-ribosylation, leading to the selective activation of its downstream osteogenic targets.[146]

Another mechanism whereby metabolic changes can influence vascular calcification include epigenetic modifications to DNA or histones. In many instances, these pathways also intersect with DNA damage signaling and senescence. Sirtuins, a family of histone deacetylases, play a role in regulating the DNA damage response and senescence in vascular SMCs and hence osteogenic differentiation and calcification. Sirt1 (sirtuin 1) is reduced in the vasculature of patients with diabetes, and its activation leads to efficient DNA repair and normalizes vascular SMC phenotype.[151] Similarly, sirtuin 6 is reduced in the vessels of patients with CKD. Studies in vitro show that sirtuin 6 acts to deacetylate Runx2, leading to its nuclear export and degradation, thus preventing osteogenic differentiation.[152]

An additional feature of the persistent DNA damage and cellular senescence is activation of the SASP (senescence-associated secretory phenotype) and activation of innate immune signals by vascular SMC, including IL-6 and BMP2 as relevant to arteriosclerotic calcification.[131,153] The connections to osteogenic BMP-Msx-Wnt (bone morphogenic protein, msh homeobox 1, wingless) signaling are presented below.

Activation of the BMP2/Msx/Wnt signaling pathways increases SMC calcification in vitro and in vivo.[154–157] Wnts are secreted, fatty acylated glycoproteins that signal through G-

protein coupled receptors of the Fzd (Frizzled) family or via GPR124 (probable G-protein–coupled receptor 124).[158–160] Signaling is modulated by coreceptors including LDL related proteins LRP5 (low-density lipoprotein receptor-related protein) and LRP6 and several transmembrane receptor tyrosine kinase-like proteins.[161,162] Wnts are fatty acylated and very hydrophobic, associated with membranes, extracellular vesicles, and lipoprotein particles.[163] The vertebrate genome encodes 19 Wnt ligands and 10 Fzd receptors with downstream signaling relays characterized as either canonical (requiring β-catenin) or noncanonical (calcium/NFAT [nuclear factor of activated T cells], Jun [fos-binding protein p39] kinase, planar cell polarity).[164,165] Alternative Wnt signaling through transcriptional coactivators YAP (yes-associated protein 1) and TAZ (WW-domain containing transcriptional regulator 1) resulting in osteogenic differentiation has also been described.[164,166]

The first robust clue that Wnt signaling might be involved in vascular aging phenotypes came from the work of Mani et al.[167] They identified that a missense mutation in LRP6 (R611C) resulted in precocious osteoporosis and coronary artery disease in an Iranian kindred. This hypomorphic allele causes dysregulated signaling bias between canonical and noncanonical Wnt relays in vascular SMCs as necessary to stabilize phenotype.[168] Consistent with this, others demonstrated that loss of SMC LRP6 increases noncanonical Wnt signals that activated SMC osteochondrogenic gene expression, and promoted vascular calcification, and arteriosclerotic stiffening in mice susceptible to atherosclerosis.[169,170]

Interestingly, expression of noncanonical Wnt ligands is increased in calcific aortic valve disease and with cardiac fibrosis.[171–174] Age-related mitochondrial dysfunction and ER stress bias towards noncanonical Wnt signaling as well.[175,176] These data suggest that development of LRP6 mimetics, or other strategies that restrain specific aspects of noncanonical Wnt signaling, may help prevent or mitigate progression of cardiovascular fibrocalcific disease processes with aging.[177]

A common theme in all of the age-associated cardiovascular Wnt-opathies is activation of innate immunity, a key feature of inflammation, and some features of cell senescence (vide infra).[177–179] Pathogen- and senescence-associated programs elevate the expression of Wnt genes either directly or indirectly via TNF, IL1-β, or RAGE (receptor for advanced glycation endproducts) ligands including oxylipids.[177] Importantly, senescent cells that accrue in aging tissues actively contribute to the inflammatory phenotypes.[180–183] A gene set containing numerous direct BMP/Wnt modulators (eg, Bmp2, Wnt2 [wingless2], Wnt16, Dkk1 [Dickkopf WNT signaling pathway inhibitor 1], etc) and targets of noncanonical Wnt action was shown to demarcate senescent cells in multiple tissues.[181] However, the conflicting literature on the role of Wnt agonists in promoting or preventing cell senescence suggests that canonical-noncanonical signaling bias and duration of signal exposure deserve additional investigation.[184,185]

Therapeutic Considerations

There are no currently approved therapies specifically targeting prevention or promoting regression of vascular or valvular calcification for the general population at any age.

Metformin is associated with reduced coronary calcification in animal and human studies[186],[187]; possible mechanisms included reduced osteoprotegerin[188] production and decreased oxidative stress.[189],[190] Senolytic combinations of dasatinib and quercetin were shown to reduce vascular calcification in animal models, attributed to reduced oxidative stress.[59],[191] Also in animal models, PARP inhibition with specific inhibitors or minocycline[192] reduced vascular calcification, as has pyrophosphate administration.[104] No therapy is available to treat valvular calcification except surgical and transcatheter interventions. Ample opportunities remain to apply known mechanisms of aging and calcification to clinical cardiovascular care.

Conclusions and Perspective

In this review, we provide a high-level summary of the current knowledge of vascular aging, emphasizing the clinical manifestations, genetic diatheses, environmental risk factors, and emerging molecular mechanisms of cardiovascular calcification. Age-associated pathways critical to the development of vascular calcification are highlighted, including DNA damage repair and senescence signals, innate immunity, activating BMP2-Msx-Wnt pathways, and the Runx2 transcription factor. Arterial SMC phenotypic switching contributes significantly to vascular aging, manifested as abnormal conduit vessel physiology and mechanical integrity due to arteriosclerotic calcification, fibrosis, matrix remodeling, and impaired contractile functions. Although key discoveries have been made, much remains to be learned concerning the regulation of arteriosclerotic calcification and its relationship to the vascular SMC phenotype with aging.

For instance, both Runx2 and Msx2 (msh homeobox 2) directly reduce the expression of SMC contractile markers and promote the osteogenic phenotype, and Runx2 and Msx2 proteins interact to form a transcriptional complex.[144],[193–195] However, O-GlcNAcylation via Ogt (O-linked N-acetylglucosamine) has also emerged as an important regulator for the master SMC transcription factors, including myocardin, SRF (serum response factor), and KLF4 (Kruppel-like factor 4).[148],[149] However, the reasons why activities of Runx2, Msx2, and Ogt in the SMC lineage—absolutely required for osteogenic differentiation and matrix deposition—can become dissociated from arterial matrix mineralization in some settings remains to be determined.[196] Incorporation of multiomics, systems biology, single-cell sequencing, and computational studies are novel approaches for the identification of new pathways, candidate drug targets, and repurposing of old drugs to treat vascular and valvular calcification.[194],[197],[198]

Endothelial cell dysfunction, with or without the endothelial-mesenchymal transition, also impacts the SMC phenotype via juxtacrine/paracrine signals that control osteogenic potential and maybe one such determinant.[199],[200] Likewise, key components of the vascular extracellular matrix such as nitrogen-2 also control SMC plasticity, and matricrine cues in cardiovascular aging are poorly characterized.[201] Of note, in utero or childhood environmental exposures impair endothelial functions decades later in adulthood.[202],[203]

Therefore, a better understanding of the vascular epigenetic landscape that regulates vascular SMC phenotypic plasticity during health span and lifespan will be needed to

mitigate age-associated vascular dysfunction. Finally, it has become abundantly apparent that duration of cardiometabolic insult exposure[204] and sex significantly impact age-dependent responses, and women experience a much steeper increase in cardiovascular disease severity with age, later in life.[205] Other age-related vasculopathies exhibit sex dimorphism as well, including aneurysmal remodeling, that is determined by sex chromosome content.[206] Thus, additional studies are warranted to uncover in even greater detail the mechanisms controlling vascular SMC phenotypic stability vs. plasticity, phenotypic switching with osteogenic reprogramming, and vascular mineralization as a function of environment, cardiometabolic insult, matricrine cues, (epi)genetics, age, and sex. Insights from these studies will afford novel targets and therapeutic strategies necessary to halt, or potentially reverse, processes of age-associated vascular calcification.

Article Information

Disclosures N.R. Sutton is an Advisor for Philips and Abbott and receives Honoraria from Zoll, Abbott, Shockwave, and Cordis. R. Malhotra—sponsored research agreement for Amgen, Bayer; Consultant for Renovocor, Third Pole, Myokardia (now Bristol Myers Squibb). S.N. Nigwekar is a Consultant for Epizon Pharma, Laboratoris Sanifit, Inozyme Pharma and reports grant support from Hope Pharma, Laboratoris Sanifit, Inozyme Pharma. P. Goyal is a Consultant for Sensorum Health. The other authors report no conflicts.

Footnotes
*N.R. Sutton and R. Malhotra contributed equally.

This article was sent to M. Luisa Iruela-Arispe, Senior Guest Editor, for review by expert referees, editorial decision, and final disposition.

For Sources of Funding and Disclosures, see pages 23–24.

Correspondence to: Yabing Chen, PhD, Department of Pathology, University of Alabama at Birmingham and Research Department, Veterans Affairs Birmingham Medical Center, 1825 University Blvd, Shelby 614 Birmingham, AL 35294. Email yabingchen@uabmc.edu

REFERENCES

1. Fernandez-Ortiz A, Jimenez-Borreguero LJ, Penalvo JL, Ordovas JM, Mocoroa A, Fernandez-Friera L, Laclaustra M, Garcia L, Molina J, Mendiguren JM, et al. The progression and early detection of subclinical atherosclerosis (pesa) study: Rationale and design. *Am Heart J.* 2013;166:990–998. doi: 10.1016/j.ahj.2013.08.024

2. Rietzschel ER, De Buyzere ML, Bekaert S, Segers P, De Bacquer D, Cooman L, Van Damme P, Cassiman P, Langlois M, van Oostveldt P, et al. Rationale, design, methods and baseline characteristics of the asklepios study. *Eur J Cardiovasc Prev Rehabil.* 2007;14:179–191. doi: 10.1097/HJR.0b013e328012c380

3. Sebastiani P, Federico A, Morris M, Gurinovich A, Tanaka T, Chandler KB, Andersen SL, Denis G, Costello CE, Ferrucci L, et al. Protein signatures of centenarians and their offspring suggest centenarians age slower than other humans. *Aging Cell.* 2021;20:e13290. doi: 10.1111/acel.13290

4. Newman AB, Glynn NW, Taylor CA, Sebastiani P, Perls TT, Mayeux R, Christensen K, Zmuda JM, Barral S, Lee JH, et al. Health and function of participants in the long life family study: a comparison with other cohorts. *Aging (Albany NY).* 2011;3:63–76. doi: 10.18632/aging.100242

5. Gurinovich A, Song Z, Zhang W, Federico A, Monti S, Andersen SL, Jennings LL, Glass DJ, Barzilai N, Millman S, et al. Effect of longevity genetic variants on the molecular aging rate. *Geroscience.* 2021;43:1237– 1251. doi: 10.1007/s11357-021-00376-4

6. Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. *J Am Coll Cardiol.* 2010;55:1318–1327. doi: 10.1016/j.jacc.2009.10.061

7. Redheuil A, Wu CO, Kachenoura N, Ohyama Y, Yan RT, Bertoni AG, Hundley GW, Duprez DA, Jacobs DR, Daniels LB, et al. Proximal aortic distensibility is an independent predictor of all-cause mortality and incident cv events: the mesa study. *J Am Coll Cardiol.* 2014;64:2619–2629. doi: 10.1016/j.jacc.2014.09.060

8. Chen Y, Zhao X, Wu H. Arterial stiffness: a focus on vascular calcification and its link to bone mineralization. *Arterioscler Thromb Vasc Biol.* 2020;40:1078–1093. doi: 10.1161/ATVBAHA.120.313131

9. Chen W, Chen Y. Cardiometabolic syndrome and vascular calcification. *CardiometabSyndr J* 2022;2:1–21.

10. Rumberger JA, Simons DB, Fitzpatrick LA, Sheedy PF, Schwartz RS. Coronary artery calcium area by electron-beam computed tomography and coronary atherosclerotic plaque area. A histopathologic correlative study. *Circulation.* 1995;92:2157–2162. doi: 10.1161/01.cir.92.8.2157

11. Rifkin RD, Parisi AF, Folland E. Coronary calcification in the diagnosis of coronary artery disease. *Am J Cardiol.* 1979;44:141–147. doi: 10.1016/0002-9149(79)90263-7

12. Hutcheson JD, Maldonado N, Aikawa E. Small entities with large impact: microcalcifications and atherosclerotic plaque vulnerability. *Curr Opin Lipidol.* 2014;25:327–332. doi: 10.1097/MOL.0000000000000105

13. Hutcheson JD, Goettsch C, Bertazzo S, Maldonado N, Ruiz JL, Goh W, Yabusaki K, Faits T, Bouten C, Franck G, et al. Genesis and growth of extracellular-vesicle-derived microcalcification in atherosclerotic plaques. *Nat Mater.* 2016;15:335–343. doi: 10.1038/nmat4519

14. Puchner SB, Liu T, Mayrhofer T, Truong QA, Lee H, Fleg JL, Nagurney JT, Udelson JE, Hoffmann U, Ferencik M. High-risk plaque detected on coronary ct angiography predicts acute coronary syndromes independent of significant stenosis in acute chest pain: results from the romicat-ii trial. *J Am Coll Cardiol.* 2014;64:684–692. doi: 10.1016/j.jacc.2014.05.039

15. Corti A, De Paolis A, Grossman P, Dinh PA, Aikawa E, Weinbaum S, Cardoso L. The effect of plaque morphology, material composition and microcalcifications on the risk of cap rupture: A structural analysis of vulnerable atherosclerotic plaques. *Frontiers in Cardiovascular Medicine.* 2022;9:1019917. doi: 10.3389/fcvm.2022.1019917

16. Mori H, Torii S, Kutyna M, Sakamoto A, Finn AV, Virmani R. Coronary artery calcification and its progression: what does it really mean?. *JACC. Cardiovasc Imaging.* 2018;11:127–142. doi: 10.1016/j.jcmg.2017.10.012

17. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. *Circ Res.* 2014;114:1852–1866. doi: 10.1161/ CIRCRESAHA.114.302721

18. Cainzos-Achirica M, Miedema MD, McEvoy JW, Al Rifai M, Greenland P, Dardari Z, Budoff M, Blumenthal RS, Yeboah J, Duprez DA, et al. Coronary artery calcium for personalized allocation of aspirin in primary prevention of cardiovascular disease in 2019: the mesa study (multi-ethnic study of atherosclerosis). *Circulation.* 2020;141:1541–1553. doi: 10.1161/ CIRCULATIONAHA.119.045010

19. Orringer CE, Blaha MJ, Blankstein R, Budoff MJ, Goldberg RB, Gill EA, Maki KC, Mehta L, Jacobson TA. The national lipid association scientific statement on coronary artery calcium scoring to guide preventive strategies for ascvd risk reduction. *J Clin Lipidol.* 2021;15:33–60. doi: 10.1016/j.jacl.2020.12.005

20. Arnett DK, Blumenthal RS, Albert MA, Buroker AB, Goldberger ZD, Hahn EJ, Himmelfarb CD, Khera A, Lloyd-Jones D, McEvoy JW, et al. 2019 acc/aha guideline on the primary prevention of cardiovascular disease: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. *J Am Coll Cardiol*. 2019;74:e177–e232.

21. McClelland RL, Jorgensen NW, Budoff M, Blaha MJ, Post WS, Kronmal RA, Bild DE, Shea S, Liu K, Watson KE, et al. 10-year coronary heart disease risk prediction using coronary artery calcium and traditional risk factors: derivation in the mesa (multi-ethnic study of atherosclerosis) with validation in the hnr (heinz nixdorf recall) study and the dhs (dallas heart study). *J Am Coll Cardiol.* 2015;66:1643–1653. doi: 10.1016/j.jacc.2015.08.035

22. Puri R, Nicholls SJ, Shao M, Kataoka Y, Uno K, Kapadia SR, Tuzcu EM, Nissen SE. Impact of statins on serial coronary calcification during atheroma progression and regression. *J Am Coll Cardiol.* 2015;65:1273–1282. doi: 10.1016/j.jacc.2015.01.036

23. Lee SE, Sung JM, Andreini D, Budoff MJ, Cademartiri F, Chinnaiyan K, Choi JH, Chun EJ, Conte E, Gottlieb I, et al. Differential association between the progression of coronary artery calcium score and coronary plaque volume progression according to statins: The progression of atherosclerotic plaque determined by computed tomographic angiography imaging (paradigm) study. *Eur Heart J Cardiovasc Imaging.* 2019;20:1307–1314. doi: 10.1093/ehjci/jez022

24. Criqui MH, Denenberg JO, Ix JH, McClelland RL, Wassel CL, Rifkin DE, Carr JJ, Budoff MJ, Allison MA. Calcium density of coronary artery plaque and risk of incident cardiovascular events. *JAMA.* 2014;311:271–278. doi: 10.1001/jama.2013.282535

25. Xian JZ, Lu M, Fong F, Qiao R, Patel NR, Abeydeera D, Iriana S, Demer LL, Tintut Y. Statin effects on vascular calcification: microarchitectural changes in aortic calcium deposits in aged hyperlipidemic mice. *Arterioscler Thromb Vasc Biol.* 2021;41:e185–e192. doi: 10.1161/ ATVBAHA.120.315737

26. Healy A, Berus JM, Christensen JL, Lee C, Mantsounga C, Dong W, Watts JP Jr, Assali M, Ceneri N, Nilson R, et al. Statins disrupt macrophage rac1 regulation leading to increased atherosclerotic plaque calcification. *Arterioscler Thromb Vasc Biol.* 2020;40:714–732. doi: 10.1161/ ATVBAHA.119.313832

27. Cainzos-Achirica M, Bittencourt MS, Osei AD, Haque W, Bhatt DL, Blumenthal RS, Blankstein R, Ray KK, Blaha MJ, Nasir K. Coronary artery calcium to improve the efficiency of randomized controlled trials in primary cardiovascular prevention. *JACC. Cardiovasc Imaging*. 2021;14:1005–

1016. doi: 10.1016/j.jcmg.2020.10.016

28. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, et al. 2018 aha/ acc/aacvpr/aapa/abc/acpm/ada/ags/apha/aspc/nla/pcna guideline on the management of blood cholesterol: a report of the american college of cardiology/american heart association task force on clinical practice guidelines. *Circulation.* 2019;139:e1082–e1143. doi: 10.1161/CIR. 0000000000000625

29. Razavi AC, Uddin SMI, Dardari ZA, Berman DS, Budoff MJ, Miedema MD, Osei AD, Obisesan OH, Nasir K, Rozanski A, et al. Coronary artery calcium for risk stratification of sudden cardiac death: the coronary artery calcium consortium. *JACC. Cardiovasc Imaging.* 2022;15:1259–1270. doi: 10.1016/j.jcmg.2022.02.011

30. Javaid A, Dardari ZA, Mitchell JD, Whelton SP, Dzaye O, Lima JAC, Lloyd-Jones DM, Budoff M, Nasir K, Berman DS, et al. Distribution of coronary artery calcium by age, sex, and race among patients 30-45 years old. *J Am Coll Cardiol.* 2022;79:1873–1886. doi: 10.1016/j. jacc.2022.02.051

31. Jayalath RW, Mangan SH, Golledge J. Aortic calcification. *Eur J Vasc Endovasc Surg.* 2005;30:476–488. doi: 10.1016/j.ejvs.2005.04.030

32. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. *J Am Coll Cardiol*. 2006;47:921–929. doi: 10.1016/j.jacc.2005.09.065

33. Aikawa E, Hutcheson JD. The developmental origin of calcific aortic stenosis. *The New England journal of medicine*. 2022;386:1372–1374. doi: 10.1056/NEJMcibr2200439

34. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. *N Engl J Med.* 1999;341:142–147. doi: 10.1056/NEJM199907153410302

35. Owens DS, Budoff MJ, Katz R, Takasu J, Shavelle DM, Carr JJ, Heckbert SR, Otto CM, Probstfield JL, Kronmal RA, et al. Aortic valve calcium independently predicts coronary and cardiovascular events in a primary prevention population. *JACC Cardiovasc Imaging* 2012;5:619–625. doi: 10.1016/j.jcmg.2011.12.023

36. Christensen JL, Tan S, Chung HE, Ghosalkar DS, Qureshi R, Chu A, Yu W, Berus J, Shah NR, Wu WC, et al. Aortic valve calcification predicts all-cause mortality independent of coronary calcification and severe stenosis. *Atherosclerosis.* 2020;307:16–20. doi: 10.1016/j. atherosclerosis.2020.06.019

37. Dzaye O, Whelton SP, Blaha MJ. Aortic valve calcium scoring on cardiac computed tomography: ready for clinical use?. *J Cardiovasc Comput Tomogr.* 2019;13:297–298. doi: 10.1016/j.jcct.2019.03.004

38. Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. *N Engl J Med.* 2018;378:1704–1714. doi: 10.1056/NEJMra1505292

39. Nigwekar SU, Zhao S, Wenger J, Hymes JL, Maddux FW, Thadhani RI, Chan KE. A nationally representative study of calcific uremic arteriolopathy risk factors. *J Am Soc Nephrol.* 2016;27:3421–3429. doi: 10.1681/ ASN.2015091065

40. McCarthy JT, El-Azhary RA, Patzelt MT, Weaver AL, Albright RC, Bridges AD, Claus PL, Davis MD, Dillon JJ, El-Zoghby ZM, et al. Survival, risk factors, and effect of treatment in 101 patients with calciphylaxis. *Mayo Clin Proc.* 2016;91:1384–1394. doi: 10.1016/j.mayocp.2016.06.025

41. Nordheim E, Dahle DO, Syse IM, Åsberg A, Reisæter AV, Hartmann A. Resolution of calciphylaxis after urgent kidney transplantation in 3 patients with end-stage kidney failure. *Transplant Direct* 2016;2:e113. doi: 10.1097/TXD. 0000000000000627

42. Wajih Z, Singer R. Successful treatment of calciphylaxis with vitamin k in a patient on haemodialysis. *Clin Kidney J*. 2022;15:354–356. doi: 10.1093/ckj/sfab209

43. Khan SS, Singer BD, Vaughan DE. Molecular and physiological manifestations and measurement of aging in humans. *Aging Cell.* 2017;16:624–633. doi: 10.1111/acel.12601

44. Horvath S. DNA methylation age of human tissues and cell types. *Genome Biol.* 2013;14:R115. doi: 10.1186/gb-2013-14-10-r115

45. Chakrabarti A, Goldstein DR, Sutton NR. Age-associated arterial calcification: the current pursuit of aggravating and mitigating factors. *Curr Opin Lipidol.* 2020;31:265–272. doi: 10.1097/MOL.0000000000000703

46. López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. *Cell.* 2013;153:1194–1217. doi: 10.1016/j.cell.2013.05.039

47. Gems D, de Magalhães JP. The hoverfly and the wasp: a critique of the hallmarks of aging as a paradigm. *Ageing Res Rev.* 2021;70:101407. doi: 10.1016/j.arr.2021.101407

48. Beyer AM, Freed JK, Durand MJ, Riedel M, Ait-Aissa K, Green P, Hockenberry JC, Morgan RG, Donato AJ, Peleg R, et al. Critical role for telomerase in the mechanism of flow-mediated dilation in the human microcirculation. *Circ Res.* 2016;118:856–866. doi: 10.1161/ circresaha.115.307918

49. Blasco MA. Telomere length, stem cells and aging. *Nat Chem Biol.* 2007;3:640–649. doi: 10.1038/nchembio.2007.38

50. Olovnikov AM. Telomeres, telomerase, and aging: origin of the theory. *Exp Gerontol.* 1996;31:443–448. doi: 10.1016/0531-5565(96)00005-8 51. de Lange T. Shelterin-mediated telomere protection. *Annu Rev Genet.* 2018;52:223–247. doi: 10.1146/annurev-genet-032918-021921

52. Morgan RG, Donato AJ, Walker AE. Telomere uncapping and vascular aging. *Am J Physiol Heart Circ Physiol.* 2018;315:H1–H5. doi: 10.1152/ajpheart.00008.2018

53. d'Adda di Fagagna F, Reaper PM, Clay-Farrace L, Fiegler H, Carr P, Von Zglinicki T, Saretzki G, Carter NP, Jackson SP. A DNA damage checkpoint response in telomere-initiated senescence. *Nature.* 2003;426:194– 198. doi: 10.1038/nature02118

54. Tchkonia T, Zhu Y, van Deursen J, Campisi J, Kirkland JL. Cellular senescence and the senescent secretory phenotype: Therapeutic opportunities. *J Clin Invest.* 2013;123:966–972. doi: 10.1172/JCI64098

55. Lin X, Li S, Wang YJ, Wang Y, Zhong JY, He JY, Cui XJ, Zhan JK, Liu YS. Exosomal notch3 from high glucose-stimulated endothelial cells regulates vascular smooth muscle cells calcification/aging. *Life Sci.* 2019; 232:116582. doi: 10.1016/j.lfs.2019.116582

56. Li S, Zhan JK, Wang YJ, Lin X, Zhong JY, Wang Y, Tan P, He JY, Cui XJ, Chen YY, et al. Exosomes from hyperglycemia-stimulated vascular endothelial cells contain versican that regulate calcification/senescence in vascular smooth muscle cells. *Cell Biosci.* 2019;9:1. doi: 10.1186/s13578-018-0263-x

57. Alique M, Ruiz-Torres MP, Bodega G, Noci MV, Troyano N, Bohorquez L, Luna C, Luque R, Carmona A, Carracedo J, et al. Microvesicles from the plasma of elderly subjects and from senescent endothelial cells promote vascular calcification. *Aging (Albany NY).* 2017;9:778–789. doi: 10.18632/aging.101191

58. Rossman MJ, Kaplon RE, Hill SD, McNamara MN, Santos-Parker JR, Pierce GL, Seals DR, Donato AJ. Endothelial cell senescence with aging in healthy humans: prevention by habitual exercise and relation to vascular endothelial function. *Am J Physiol Heart Circ Physiol.* 2017;313:H890– H895. doi: 10.1152/ajpheart.00416.2017

59. Roos CM, Zhang B, Palmer AK, Ogrodnik MB, Pirtskhalava T, Thalji NM, Hagler M, Jurk D, Smith LA, Casaclang-Verzosa G, et al. Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. *Aging Cell.* 2016;15:973–977. doi: 10.1111/acel.12458

60. Meerman M, Driessen R, van Engeland NCA, Bergsma I, Steenhuijsen JLG, Kozono D, Aikawa E, Hjortnaes J, Bouten CVC. Radiation induces valvular interstitial cell calcific response in an in vitro model of calcific aortic valve disease. *Front Cardiovasc Med.* 2021;8:687885. doi: 10.3389/ fcvm.2021.687885

61. Hoeijmakers JH. DNA damage, aging, and cancer. *N Engl J Med.* 2009;361:1475–1485. doi: 10.1056/nejmra0804615

62. Chellan B, Sutton NR, Hofmann Bowman MA. S100/rage-mediated inflammation and modified cholesterol lipoproteins as mediators of osteoblastic differentiation of vascular smooth muscle cells. *Front Cardiovasc Med.* 2018;5:163. doi: 10.3389/fcvm.2018.00163

63. Franceschi C, Bonafe M, Valensin S, Olivieri F, De Luca M, Ottaviani E, De Benedictis G. Inflamm-aging. An evolutionary perspective on immunosenescence. *Ann N Y Acad Sci.* 2000;908:244–254. doi: 10.1111/j. 1749-6632.2000.tb06651.x

64. Rymut N, Heinz J, Sadhu S, Hosseini Z, Riley CO, Marinello M, Maloney J, MacNamara KC, Spite M, Fredman G. Resolvin d1 promotes efferocytosis in aging by limiting senescent cell-induced mertk cleavage. *FASEB J.* 2020;34:597–609. doi: 10.1096/fj.201902126R

65. Sadhu S, Decker C, Sansbury BE, Marinello M, Seyfried A, Howard J, Mori M, Hosseini Z, Arunachalam T, Finn AV, et al. Radiation-induced macrophage senescence impairs resolution programs and drives cardiovascular inflammation. *J Immunol.* 2021;207:1812–1823. doi: 10.4049/ jimmunol.2100284

66. Stojanovic SD, Fiedler J, Bauersachs J, Thum T, Sedding DG. Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis. *Eur Heart J.* 2020;41:2983–2996. doi: 10.1093/eurheartj/ehz919

67. Buendia P, Montes de Oca A, Madueno JA, Merino A, Martin-Malo A, Aljama P, Ramirez R, Rodriguez M, Carracedo J. Endothelial microparticles mediate inflammation-induced vascular calcification. *FASEB J.* 2015;29:173–181. doi: 10.1096/fj.14-249706

68. Csiszar A, Ahmad M, Smith KE, Labinskyy N, Gao Q, Kaley G, Edwards JG, Wolin MS, Ungvari Z. Bone morphogenetic protein-2 induces proinflammatory endothelial phenotype. *Am J Pathol.* 2006;168:629–638. doi: 10.2353/ajpath.2006.050284

69. Henze LA, Luong TTD, Boehme B, Masyout J, Schneider MP, Brachs S, Lang F, Pieske B, Pasch A, Eckardt KU, et al. Impact of c-reactive protein on osteo-/chondrogenic transdifferentiation and calcification of vascular smooth muscle cells. *Aging (Albany NY).* 2019;11:5445–5462. doi: 10.18632/aging.102130

70. Chen BH, Marioni RE, Colicino E, Peters MJ, Ward-Caviness CK, Tsai PC, Roetker NS, Just AC, Demerath EW, Guan W, et al. DNA methylation-based measures of biological age: meta-analysis predicting time to death. *Aging.* 2016;8:1844–1865. doi: 10.18632/aging.101020

71. Marioni RE, Shah S, McRae AF, Chen BH, Colicino E, Harris SE, Gibson J, Henders AK, Redmond P, Cox SR, et al. DNA methylation age of blood predicts all-cause mortality in later life. *Genome Biol.* 2015;16:25. doi: 10.1186/s13059-015-0584-6

72. Perna L, Zhang Y, Mons U, Holleczek B, Saum KU, Brenner H. Epigenetic age acceleration predicts cancer, cardiovascular, and all-cause mortality in a german case cohort. *Clinical epigenetics* 2016;8:64. doi: 10.1186/s13148-016-0228-z

73. Badi I, Mancinelli L, Polizzotto A, Ferri D, Zeni F, Burba I, Milano G, Brambilla F, Saccu C, Bianchi ME, et al. Mir-34a promotes vascular smooth muscle cell calcification by downregulating sirt1 (sirtuin 1) and axl (axl receptor tyrosine kinase). *Arterioscler Thromb Vasc Biol.* 2018;38:2079–2090. doi: 10.1161/ATVBAHA.118.311298

74. Kwon DH, Eom GH, Ko JH, Shin S, Joung H, Choe N, Nam YS, Min HK, Kook T, Yoon S, et al. Mdm2 e3 ligase-mediated ubiquitination and degradation of hdac1 in vascular calcification. *Nat Commun.* 2016;7:10492. doi: 10.1038/ncomms10492

75. Du Y, Gao C, Liu Z, Wang L, Liu B, He F, Zhang T, Wang Y, Wang X, Xu M, et al. Upregulation of a disintegrin and metalloproteinase with thrombospondin motifs-7 by mir-29 repression mediates vascular smooth muscle calcification. *Arterioscler Thromb Vasc Biol.* 2012;32:2580–2588. doi: 10.1161/ATVBAHA.112.300206

76. Chao CT, Liu YP, Su SF, Yeh HY, Chen HY, Lee PJ, Chen WJ, Lee YM, Huang JW, Chiang CK, et al. Circulating microrna-125b predicts the presence and progression of uremic vascular calcification. *Arterioscler Thromb Vasc Biol.* 2017;37:1402–1414. doi: 10.1161/ATVBAHA.117.309566

77. Wang C, Xu W, An J, Liang M, Li Y, Zhang F, Tong Q, Huang K. Poly(adpribose) polymerase 1 accelerates vascular calcification by upregulating runx2. *Nat Commun.* 2019;10:1203. doi: 10.1038/s41467-019-09174-1

78. Harman JL, Dobnikar L, Chappell J, Stokell BG, Dalby A, Foote K, Finigan A, Freire-Pritchett P, Taylor AL, Worssam MD, et al. Epigenetic regulation of vascular smooth muscle cells by histone h3 lysine 9 dimethylation attenuates target gene-induction by inflammatory signaling. *Arterioscler Thromb Vasc Biol.* 2019;39:2289–2302. doi: 10.1161/ATVBAHA.119.312765

79. Liu M, Espinosa-Diez C, Mahan S, Du M, Nguyen AT, Hahn S, Chakraborty R, Straub AC, Martin KA, Owens GK, et al. H3k4 di-methylation governs smooth muscle lineage identity and promotes vascular homeostasis by restraining plasticity. *Dev Cell.* 2021;56:2765–2782.e10. doi: 10.1016/j.devcel.2021.09.001

80. Kullo IJ, Lewis CM, Inouye M, Martin AR, Ripatti S, Chatterjee N. Polygenic scores in biomedical research. *Nat Rev Genet.* 2022;23:524–532. doi: 10.1038/s41576-022-00470-z

81. Isgut M, Sun J, Quyyumi AA, Gibson G. Highly elevated polygenic risk scores are better predictors of myocardial infarction risk early in life than later. *Genome Med.* 2021;13:13. doi: 10.1186/s13073-021-00828-8

82. Mars N, Koskela JT, Ripatti P, Kiiskinen TTJ, Havulinna AS, Lindbohm JV, Ahola-Olli A, Kurki M, Karjalainen J, Palta P, et al; FinnGen. Polygenic and clinical risk scores and their impact on age at onset and prediction of cardiometabolic diseases and common cancers. *Nat Med.* 2020;26:549–557. doi: 10.1038/s41591-020-0800-0

83. Khera AV, Chaffin M, Aragam KG, Haas ME, Roselli C, Choi SH, Natarajan P, Lander ES, Lubitz SA, Ellinor PT, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. *Nat Genet.* 2018;50:1219–1224. doi: 10.1038/s41588-018-0183-z

84. Abul-Husn NS, Manickam K, Jones LK, Wright EA, Hartzel DN, Gonzaga- Jauregui C, O'Dushlaine C, Leader JB, Lester Kirchner H, Lindbuchler DM, et al. Genetic identification of familial hypercholesterolemia within a single u.S. Health care system. *Science (New York, N.Y.).* 2016;354:aaf7000. doi: 10.1126/science.aaf7000

85. Jiang X, Holmes C, McVean G. The impact of age on genetic risk for common diseases. *PLoS Genet.* 2021;17:e1009723. doi: 10.1371/journal. pgen.1009723

86. Thanassoulis G, Peloso GM, Pencina MJ, Hoffmann U, Fox CS, Cupples LA, Levy D, D'Agostino RB, Hwang SJ, O'Donnell CJ. A genetic risk score is associated with incident cardiovascular disease and coronary artery calcium: the framingham heart study. *Circ Cardiovasc Genet.* 2012;5:113–121. doi: 10.1161/CIRCGENETICS.111.961342

87. Natarajan P, Young R, Stitziel NO, Padmanabhan S, Baber U, Mehran R, Sartori S, Fuster V, Reilly DF, Butterworth A, et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. *Circulation.* 2017;135:2091–2101. doi: 10.1161/CIRCULATIONAHA.116.024436

88. Salfati E, Nandkeolyar S, Fortmann SP, Sidney S, Hlatky MA, Quertermous T, Go AS, Iribarren C, Herrington DM, Goldstein BA, et al. Susceptibility loci for clinical coronary artery disease and subclinical coronary atherosclerosis throughout the life-course. *Circ Cardiovasc Genet.* 2015;8:803–811. doi: 10.1161/CIRCGENETICS.114.001071

89. Severance LM, Contijoch FJ, Carter H, Fan CC, Seibert TM, Dale AM, McVeigh ER. Using a genetic risk score to calculate the optimal age for an individual to undergo coronary artery calcium screening. *J Cardiovasc Comput Tomogr.* 2019;13:203–210. doi: 10.1016/j.jcct.2019.05.005

90. Khera AV, Emdin CA, Drake I, Natarajan P, Bick AG, Cook NR, Chasman DI, Baber U, Mehran R, Rader DJ, et al. Genetic risk, adherence to a healthy lifestyle, and coronary disease. *N Engl J Med.* 2016;375:2349–2358. doi: 10.1056/NEJMoa1605086

91. Widén E, Junna N, Ruotsalainen S, Surakka I, Mars N, Ripatti P, Partanen JJ, Aro J, Mustonen P, Tuomi T, et al. How communicating polygenic and clinical risk for atherosclerotic cardiovascular disease impacts health behavior: an observational follow-up study. *Circul Genom Precis Med.* 2022;15: e003459. doi: 10.1161/CIRCGEN.121.003459

92. Muse ED, Chen SF, Liu S, Fernandez B, Schrader B, Molparia B, León AN, Lee R, Pubbi N, Mejia N, et al. Impact of polygenic risk communication: an observational mobile application-based coronary artery disease study. *NPJ Digital Med.* 2022;5:30. doi: 10.1038/s41746-022-00578-w

93. O'Sullivan JW, Raghavan S, Marquez-Luna C, Luzum JA, Damrauer SM, Ashley EA, O'Donnell CJ, Willer CJ, Natarajan P; American Heart Association Council on Genomic and Precision Medicine; Council on Clinical Cardiology; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; Council on Lifestyle and Cardiometabolic Health; and Council on Peripheral Vascular Disease. Polygenic risk scores for cardiovascular disease: A scientific statement from the american heart association. *Circulation.* 2022;146:e93–e118. doi: 10.1161/CIR.0000000000001077

94. Elliott J, Bodinier B, Bond TA, Chadeau-Hyam M, Evangelou E, Moons KGM, Dehghan A, Muller DC, Elliott P, Tzoulaki I. Predictive accuracy of a polygenic risk score-enhanced prediction model vs a clinical risk score for coronary artery disease. *JAMA.* 2020;323:636–645. doi: 10.1001/jama.2019.22241

95. Hindy G, Aragam KG, Ng K, Chaffin M, Lotta LA, Baras A, Drake I, Orho-Melander M, Melander O, Kathiresan S, et al; Regeneron Genetics Center. Genome-wide polygenic score, clinical risk factors, and long-term trajectories of coronary artery disease. *Arterioscler Thromb Vasc Biol.* 2020;40:2738–2746. doi: 10.1161/ATVBAHA.120.314856

96. Riveros-Mckay F, Weale ME, Moore R, Selzam S, Krapohl E, Sivley RM, Tarran WA, Sørensen P, Lachapelle AS, Griffiths JA, et al. Integrated polygenic tool substantially enhances coronary artery disease prediction. *Circ Genom Precis Med*. 2021;14:e003304. doi: 10.1161/CIRCGEN.120.003304

97. Sun L, Pennells L, Kaptoge S, Nelson CP, Ritchie SC, Abraham G, Arnold M, Bell S, Bolton T, Burgess S, et al. Polygenic risk scores in cardiovascular risk prediction: a cohort study and modelling analyses. *PLoS Med.* 2021;18:e1003498. doi: 10.1371/journal.pmed.1003498

98. Weale ME, Riveros-Mckay F, Selzam S, Seth P, Moore R, Tarran WA, Gradovich E, Giner-Delgado C, Palmer D, Wells D, et al. Validation of an integrated risk tool, including polygenic risk score, for atherosclerotic cardiovascular disease in multiple ethnicities and ancestries. *Am J Cardiol.* 2021;148:157–164. doi: 10.1016/j.amjcard.2021.02.032

99. Lu X, Liu Z, Cui Q, Liu F, Li J, Niu X, Shen C, Hu D, Huang K, Chen J, et al. A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective chinese cohort study. *Eur Heart J.* 2022;43:1702–1711. doi: 10.1093/eurheartj/ehac093

100. Steinfeldt J, Buergel T, Loock L, Kittner P, Ruyoga G, Zu Belzen JU, Sasse S, Strangalies H, Christmann L, Hollmann N, et al. Neural networkbased integration of polygenic and clinical information: Development and validation of a prediction model for 10-year risk of major adverse cardiac events in the uk biobank cohort. *Lancet Digit Health.* 2022;4:e84–e94. doi: 10.1016/S2589-7500(21)00249-1

101. Rutsch F, Buers I, Nitschke Y. Hereditary disorders of cardiovascular calcification. *Arterioscler Thromb Vasc Biol.* 2021;41:35–47. doi: 10.1161/ATVBAHA.120.315577

102. Huang Z, Xie N, Illes P, Di Virgilio F, Ulrich H, Semyanov A, Verkhratsky A, Sperlagh B, Yu SG, Huang C, et al. From purines to purinergic signalling: molecular functions and human diseases. *Signal Transduct Target Ther.* 2021;6:162. doi: 10.1038/s41392-021-00553-z

103. Minor M, Alcedo KP, Battaglia RA, Snider NT. Cell type- and tissue-specific functions of ecto-5'-nucleotidase (cd73). *Am J Physiol Cell Physiol*. 2019;317:C1079–C1092. doi: 10.1152/ajpcell.00285.2019

104. Villa-Bellosta R, Rivera-Torres J, Osorio FG, Acin-Perez R, Enriquez JA, Lopez-Otin C, Andres V. Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of hutchinson-gilford progeria syndrome that is ameliorated on pyrophosphate treatment. *Circulation.* 2013;127:2442–2451. doi: 10.1161/CIRCULATIONAHA.112.000571

105. O'Donnell CJ, Kavousi M, Smith AV, Kardia SL, Feitosa MF, Hwang SJ, Sun YV, Province MA, Aspelund T, Dehghan A, et al; CARDIoGRAM Consortium. Genome-wide association study for coronary artery calcification with follow-up in myocardial infarction. *Circulation.* 2011;124:2855–2864. doi: 10.1161/CIRCULATIONAHA.110.974899

106. Gupta RM, Hadaya J, Trehan A, Zekavat SM, Roselli C, Klarin D, Emdin CA, Hilvering CRE, Bianchi V, Mueller C, et al. A genetic variant associated with five vascular diseases is a distal regulator of endothelin-1 gene expression. *Cell.* 2017;170:522–533.e15. doi: 10.1016/j.cell.2017.06.049

107. Natarajan P, Bis JC, Bielak LF, Cox AJ, Dörr M, Feitosa MF, Franceschini N, Guo X, Hwang SJ, Isaacs A, et al; CHARGE Consortium. Multiethnic exomewide association study of subclinical atherosclerosis. *Circ Cardiovasc Genet.* 2016;9:511–520. doi: 10.1161/CIRCGENETICS.116.001572

108. Malhotra R, Mauer AC, Lino Cardenas CL, Guo X, Yao J, Zhang X, Wunderer F, Smith AV, Wong Q, Pechlivanis S, et al. Hdac9 is implicated in atherosclerotic aortic calcification and affects vascular smooth muscle cell phenotype. *Nat Genet.* 2019;51:1580–1587. doi: 10.1038/s41588-019-0514-8

109. Lecce L, Xu Y, V'Gangula B, Chandel N, Pothula V, Caudrillier A, Santini MP, d'Escamard V, Ceholski DK, Gorski PA, et al. Histone deacetylase 9 promotes endothelial-mesenchymal transition and an unfavorable atherosclerotic plaque phenotype. *J Clin Invest.* 2021;131: e131178. doi: 10.1172/JCI131178

110. Nurnberg ST, Guerraty MA, Wirka RC, Rao HS, Pjanic M, Norton S, Serrano F, Perisic L, Elwyn S, Pluta J, et al. Genomic profiling of human vascular cells identifies twist1 as a causal gene for common vascular diseases. *PLoS Genet.* 2020;16:e1008538. doi: 10.1371/journal.pgen.1008538

111. Thanassoulis G, Campbell CY, Owens DS, Smith JG, Smith AV, Peloso GM, Kerr KF, Pechlivanis S, Budoff MJ, Harris TB, et al; CHARGE Extracoronary Calcium Working Group. Genetic associations with valvular calcification and aortic stenosis. *N Engl J Med.* 2013;368:503–512. doi: 10.1056/NEJMoa1109034

112. Helgadottir A, Thorleifsson G, Gretarsdottir S, Stefansson OA, Tragante V, Thorolfsdottir RB, Jonsdottir I, Bjornsson T, Steinthorsdottir V, Verweij N, et al. Genome-wide analysis yields new loci associating with aortic valve stenosis. *Nat Commun.* 2018;9:987. doi: 10.1038/s41467-018-03252-6

113. Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Höhne W, Schauer G, Lehmann M, Roscioli T, Schnabel D, et al. Mutations in enpp1 are associated with "idiopathic" infantile arterial calcification. *Nat Genet.* 2003;34:379–381. doi: 10.1038/ng1221

114. St Hilaire C, Ziegler SG, Markello TC, Brusco A, Groden C, Gill F, Carlson-Donohoe H, Lederman RJ, Chen MY, Yang D, et al. Nt5e mutations and arterial calcifications. *N Engl J Med.* 2011;364:432–442. doi: 10.1056/NEJMoa0912923

115. Jansen RS, Küçükosmanoglu A, de Haas M, Sapthu S, Otero JA, Hegman IE, Bergen AA, Gorgels TG, Borst P, van de Wetering K. Abcc6 prevents ectopic mineralization seen in pseudoxanthoma elasticum by inducing cellular nucleotide release. *Proc Natl Acad Sci USA.* 2013;110:20206–20211. doi: 10.1073/pnas.1319582110

116. St Hilaire C. Medial arterial calcification: a significant and independent contributor of peripheral artery disease. *Arterioscler Thromb Vasc Biol.* 2022;42:253–260. doi: 10.1161/ATVBAHA.121.316252

117. Jin H, St Hilaire C, Huang Y, Yang D, Dmitrieva NI, Negro A, Schwartzbeck R, Liu Y, Yu Z, Walts A, et al. Increased activity of tnap compensates for reduced adenosine production and promotes ectopic calcification in the genetic disease acdc. *Sci Signal.* 2016;9:ra121. doi: 10.1126/scisignal.aaf9109

118. Sutton NR, Hofmann Bowman MA. Reining in peripheral arterial calcification. *Arterioscler Thromb Vasc Biol.* 2020;40:1614–1616. doi: 10.1161/ATVBAHA.120.314665

119. Moorhead WJ 3rd, Chu CC, Cuevas RA, Callahan J, Wong R, Regan C, Boufford CK, Sur S, Liu M, Gomez D, et al. Dysregulation of foxo1 (forkhead box o1 protein) drives calcification in arterial calcification due to deficiency of cd73 and is present in peripheral artery disease. *Arterioscler Thromb Vasc Biol.* 2020;40:1680–1694. doi: 10.1161/ATVBAHA.119.313765

120. Ziegler SG, Ferreira CR, MacFarlane EG, Riddle RC, Tomlinson RE, Chew EY, Martin L, Ma CT, Sergienko E, Pinkerton AB, et al. Ectopic calcification in pseudoxanthoma elasticum responds to inhibition of tissuenonspecific alkaline phosphatase. *Sci Transl Med.* 2017;9:eaal1669. doi: 10.1126/scitranslmed.aal1669

121. Rutsch F, MacDougall M, Lu C, Buers I, Mamaeva O, Nitschke Y, Rice GI, Erlandsen H, Kehl HG, Thiele H, et al. A specific ifih1 gain-offunction mutation causes singleton-merten syndrome. *Am J Hum Genet.* 2015;96:275–282. doi: 10.1016/j.ajhg.2014.12.014

122. Eriksson M, Brown WT, Gordon LB, Glynn MW, Singer J, Scott L, Erdos MR, Robbins CM, Moses TY, Berglund P, et al. Recurrent de novo point mutations in lamin a cause hutchinson-gilford progeria syndrome. *Nature.* 2003;423:293–298. doi: 10.1038/nature01629

123. De Sandre-Giovannoli A, Bernard R, Cau P, Navarro C, Amiel J, Boccaccio I, Lyonnet S, Stewart CL, Munnich A, Le Merrer M, et al. Lamin a truncation in hutchinson-gilford progeria. *Science.* 2003;300:2055. doi: 10.1126/science.1084125

124. Jaiswal S, Natarajan P, Silver AJ, Gibson CJ, Bick AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *N Engl J Med.* 2017;377:111–121. doi: 10.1056/NEJMoa1701719

125. Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, Wu CL, Sano S, Muralidharan S, Rius C, et al. Clonal hematopoiesis associated with tet2 deficiency accelerates atherosclerosis development in mice. *Science.* 2017;355:842–847. doi: 10.1126/ science.aag1381

126. Cassidy-Bushrow AE, Bielak LF, Levin AM, Sheedy PF 2nd, Turner ST, Boerwinkle E, Lin X, Kardia SL, Peyser PA. Matrix gla protein gene polymorphism is associated with increased coronary artery calcification progression. *Arterioscler Thromb Vasc Biol.* 2013;33:645–651. doi: 10.1161/ATVBAHA.112.300491

127. Lanzer P, Boehm M, Sorribas V, Thiriet M, Janzen J, Zeller T, St Hilaire C, Shanahan C. Medial vascular calcification revisited: review and perspectives. *Eur Heart J.* 2014;35:1515–1525. doi: 10.1093/eurheartj/ehu163

128. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. *Am J Kidney Dis.* 1998;32:S112–S119. doi: 10.1053/ajkd.1998.v32.pm9820470

129. Shroff R, Dégi A, Kerti A, Kis E, Cseprekál O, Tory K, Szabó AJ, Reusz GS. Cardiovascular risk assessment in children with chronic kidney disease. *Pediatric nephrology (Berlin, Germany).* 2013;28:875–884. doi: 10.1007/s00467-012-2325-3

130. Shroff RC, McNair R, Figg N, Skepper JN, Schurgers L, Gupta A, Hiorns M, Donald AE, Deanfield J, Rees L, et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. *Circulation.* 2008;118:1748–1757. doi: 10.1161/CIRCULATIONAHA.108.783738

131. Sanchis P, Ho CY, Liu Y, Beltran LE, Ahmad S, Jacob AP, Furmanik M, Laycock J, Long DA, Shroff R, et al. Arterial "inflammaging" drives vascular calcification in children on dialysis. *Kidney Int.* 2019;95:958–972. doi: 10.1016/j.kint.2018.12.014

132. Luttropp K, Debowska M, Lukaszuk T, Bobrowski L, Carrero JJ, Qureshi AR, Stenvinkel P, Lindholm B, Waniewski J, Nordfors L. Genotypic and phenotypic predictors of inflammation in patients with chronic kidney disease. *Nephrol Dial Transplant* 2016;31:2033–2040. doi: 10.1093/ndt/gfw066

133. Bartoli-Leonard F, Wilkinson FL, Schiro A, Serracino Inglott F, Alexander MY, Weston R. Loss of sirt1 in diabetes accelerates DNA damage-induced vascular calcification. *Cardiovasc Res.* 2021;117:836–849. doi: 10.1093/cvr/cvaa134

134. Hirakawa Y, Jao TM, Inagi R. Pathophysiology and therapeutics of premature ageing in chronic kidney disease, with a focus on glycative stress. *Clin Exp Pharmacol Physiol.* 2017;44:70–77. doi: 10.1111/1440- 1681.12777

135. Komaba H, Fukagawa M. Phosphate-a poison for humans? *Kidney Int.* 2016;90:753–763. doi: 10.1016/j.kint.2016.03.039

136. Payne RA, Wilkinson IB, Webb DJ. Arterial stiffness and hypertension: emerging concepts. *Hypertension (Dallas, Tex.: 1979).* 2010;55:9–14. doi: 10.1161/HYPERTENSIONAHA.107.090464

137. Lacolley P, Regnault V, Avolio AP. Smooth muscle cell and arterial aging: basic and clinical aspects. *Cardiovasc Res.* 2018;114:513–528. doi: 10.1093/cvr/cvy009

138. Chen Y, Zhao X, Wu H. Transcriptional programming in arteriosclerotic disease: a multifaceted function of the runx2 (runt-related transcription factor 2). *Arterioscler Thromb Vasc Biol.* 2021;41:20–34. doi: 10.1161/ATVBAHA.120.313791

139. Duer M, Cobb AM, Shanahan CM. DNA damage response: a molecular lynchpin in the pathobiology of arteriosclerotic calcification. *Arterioscler Thromb Vasc Biol.* 2020;40:e193–e202. doi: 10.1161/ATVBAHA.120.313792

140. Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM, McDonald JM, Chen Y. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor runx2 by akt signaling. *J Biol Chem.* 2008;283:15319–15327. doi: 10.1074/jbc.M800021200

141. Otto F, Thornell AP, Crompton T, Denzel A, Gilmour KC, Rosewell IR, Stamp GW, Beddington RS, Mundlos S, Olsen BR, et al. Cbfa1, a candidate gene for cleidocranial dysplasia syndrome, is essential for osteoblast differentiation and bone development. *Cell.* 1997;89:765–771. doi: 10.1016/s0092-8674(00)80259-7

142. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, Deguchi K, Shimizu Y, Bronson RT, Gao YH, Inada M, et al. Targeted disruption of cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. *Cell.* 1997;89:755–764. doi: 10.1016/s0092-8674(00)80258-5

143. Ducy P, Starbuck M, Priemel M, Shen J, Pinero G, Geoffroy V, Amling M, Karsenty G. A cbfa1-dependent genetic pathway controls bone formation beyond embryonic development. *Genes Dev.* 1999;13:1025–1036. doi: 10.1101/gad.13.8.1025

144. Sun Y, Byon CH, Yuan K, Chen J, Mao X, Heath JM, Javed A, Zhang K, Anderson PG, Chen Y. Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. *Circ Res.* 2012;111:543–552. doi: 10.1161/CIRCRESAHA.112.267237

145. Lin ME, Chen T, Leaf EM, Speer MY, Giachelli CM. Runx2 expression in smooth muscle cells is required for arterial medial calcification in mice. *Am J Pathol.* 2015;185:1958–1969. doi: 10.1016/j.ajpath.2015.03.020

146. Cobb AM, Yusoff S, Hayward R, Ahmad S, Sun M, Verhulst A, D'Haese PC, Shanahan CM. Runx2 (runt-related transcription factor 2) links the DNA damage response to osteogenic reprogramming and apoptosis of vascular smooth muscle cells. *Arterioscler Thromb Vasc Biol.* 2021;41:1339–1357. doi: 10.1161/ATVBAHA.120.315206

147. Heath JM, Sun Y, Yuan K, Bradley WE, Litovsky S, Dell'Italia LJ, Chatham JC, Wu H, Chen Y. Activation of akt by o-linked n-acetylglucosamine induces vascular calcification in diabetes mellitus. *Circ Res.* 2014;114: 1094–1102. doi: 10.1161/CIRCRESAHA.114.302968

148. Ni Z, Deng J, Potter CMF, Nowak WN, Gu W, Zhang Z, Chen T, Chen Q, Hu Y, Zhou B, et al. Recipient c-kit lineage cells repopulate smooth muscle cells of transplant arteriosclerosis in mouse models. *Circ Res.* 2019;125:223–241. doi: 10.1161/CIRCRESAHA.119.314855

149. Paredes F, Williams HC, Quintana RA, San Martin A. Mitochondrial protein poldip2 (polymerase delta interacting protein 2) controls vascular smooth muscle differentiated phenotype by o-linked glcnac (n-acetylglucosamine) transferase-dependent inhibition of a ubiquitin proteasome system. *Circ Res.* 2020;126:41–56. doi: 10.1161/CIRCRESAHA.119.315932

150. Chen Y, Zhao X, Wu H. Metabolic stress and cardiovascular disease in diabetes mellitus: the role of protein o-glcnac modification. *Arterioscler Thromb Vasc Biol.* 2019;39:1911–1924. doi: 10.1161/ATVBAHA.119.312192

151. Bartoli-Leonard F, Zimmer J, Aikawa E. Innate and adaptive immunity: the understudied driving force of heart valve disease. *Cardiovasc Res.* 2021;117:2506–2524. doi: 10.1093/cvr/cvab273

152. Li W, Feng W, Su X, Luo D, Li Z, Zhou Y, Zhu Y, Zhang M, Chen J, Liu B, et al. Sirt6 protects vascular smooth muscle cells from osteogenic transdif[AQ22] ferentiation via runx2 in chronic kidney disease. *J Clin Invest.* 2022;132

153. Liu Y, Drozdov I, Shroff R, Beltran LE, Shanahan CM. Prelamin a accelerates vascular calcification via activation of the DNA damage response and senescence-associated secretory phenotype in vascular smooth muscle cells. *Circ Res.* 2013;112:e99–109. doi: 10.1161/CIRCRESAHA.111.300543

154. Al-Aly Z, Shao JS, Lai CF, Huang E, Cai J, Behrmann A, Cheng SL, Towler DA. Aortic msx2-wnt calcification cascade is regulated by tnf-alphadependent signals in diabetic ldlr-/- mice. *Arterioscler Thromb Vasc Biol.* 2007;27:2589–2596. doi: 10.1161/ATVBAHA.107.153668

155. Shao JS, Aly ZA, Lai CF, Cheng SL, Cai J, Huang E, Behrmann A, Towler DA. Vascular bmp msx2 wnt signaling and oxidative stress in arterial calcification. *Ann N Y Acad Sci.* 2007;1117:40–50. doi: 10.1196/annals.1402.075

156. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine wnt signals. *J Clin Invest.* 2005;115:1210–1220. doi: 10.1172/JCI24140

157. Cheng SL, Behrmann A, Shao JS, Ramachandran B, Krchma K, Bello Arredondo Y, Kovacs A, Mead M, Maxson R, Towler DA. Targeted reduction of vascular msx1 and msx2 mitigates arteriosclerotic calcification and aortic stiffness in ldlr-deficient mice fed diabetogenic diets. *Diabetes.* 2014;63:4326–4337. doi: 10.2337/db14-0326

158. Nile AH, Hannoush RN. Fatty acylation of wnt proteins. *Nat Chem Biol.* 2016;12:60–69. doi: 10.1038/nchembio.2005

159. Wang Y, Chang H, Rattner A, Nathans J. Frizzled receptors in development and disease. *Curr Top Dev Biol.* 2016;117:113–139. doi: 10.1016/bs. ctdb.2015.11.028

160. Cho C, Smallwood PM, Nathans J. Reck and gpr124 are essential receptor cofactors for wnt7a/wnt7b-specific signaling in mammalian cns angiogenesis and blood-brain barrier regulation. *Neuron.* 2017;95:1056–1073.e5. doi: 10.1016/j.neuron.2017.07.031

161. Davidson G. Lrps in wnt signalling. *Handb Exp Pharmacol.* 2021;269:45– 73. doi: 10.1007/164_2021_526

162. Green J, Nusse R, van Amerongen R. The role of ryk and ror receptor tyrosine kinases in wnt signal transduction. *Cold Spring Harbor Perspect Biol.* 2014;6:a009175. doi: 10.1101/cshperspect.a009175

163. Routledge D, Scholpp S. Mechanisms of intercellular wnt transport. *Development (Cambridge, England)*. 2019;146:dev176073. doi: 10.1242/dev.176073

164. Albrecht LV, Tejeda-Muñoz N, De Robertis EM. Cell biology of canonical wnt signaling. *Annu Rev Cell Dev Biol.* 2021;37:369–389. doi: 10.1146/annurev-cellbio-120319-023657

165. Abdolmaleki F, Ahmadpour-Yazdi H, Hayat SMG, Gheibi N, Johnston TP, Sahebkar A. Wnt network: a brief review of pathways and multifunctional components. *Crit Rev Eukaryot Gene Expr.* 2020;30:1–18. doi: 10.1615/ CritRevEukaryotGeneExpr.2019025774

166. Park HW, Kim YC, Yu B, Moroishi T, Mo JS, Plouffe SW, Meng Z, Lin KC, Yu FX, Alexander CM, et al. Alternative wnt signaling activates yap/taz. *Cell.* 2015;162:780–794. doi: 10.1016/j.cell.2015.07.013

167. Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, Nelson-Williams C, Carew KS, Mane S, Najmabadi H, Wu D, et al. Lrp6 mutation in a family with early coronary disease and metabolic risk factors. *Science (New York, N.Y.).* 2007;315:1278–1282. doi: 10.1126/science.1136370

168. Srivastava R, Zhang J, Go GW, Narayanan A, Nottoli TP, Mani A. Impaired lrp6-tcf7l2 activity enhances smooth muscle cell plasticity and causes coronary artery disease. *Cell Rep.* 2015;13:746–759. doi: 10.1016/j. celrep.2015.09.028

169. Cheng SL, Ramachandran B, Behrmann A, Shao JS, Mead M, Smith C, Krchma K, Bello Arredondo Y, Kovacs A, Kapoor K, et al. Vascular smooth muscle lrp6 limits arteriosclerotic calcification in diabetic ldlr-/- mice by restraining noncanonical wnt signals. *Circ Res.* 2015;117:142–156. doi: 10.1161/CIRCRESAHA.117.306712

170. Ramachandran B, Stabley JN, Cheng SL, Behrmann AS, Gay A, Li L, Mead M, Kozlitina J, Lemoff A, Mirzaei H, et al. A gtpase-activating proteinbinding protein (g3bp1)/antiviral protein relay conveys arteriosclerotic wnt signals in aortic smooth muscle cells. *J Biol Chem.* 2018;293:7942–7968. doi: 10.1074/jbc.RA118.002046

171. Albanese I, Yu B, Al-Kindi H, Barratt B, Ott L, Al-Refai M, de Varennes B, Shum-Tim D, Cerruti M, Gourgas O, et al. Role of noncanonical wnt signaling pathway in human aortic valve calcification. *Arterioscler Thromb Vasc Biol.* 2017;37:543–552. doi: 10.1161/ATVBAHA.116.308394

172. Abraityte A, Vinge LE, Askevold ET, Lekva T, Michelsen AE, Ranheim T, Alfsnes K, Fiane A, Aakhus S, Lunde IG, et al. Wnt5a is elevated in heart failure and affects cardiac fibroblast function. *J Mol Med (Berlin, Germany).* 2017;95:767–777. doi: 10.1007/s00109-017-1529-1

173. Działo E, Rudnik M, Koning RI, Czepiel M, Tkacz K, Baj-Krzyworzeka M, Distler O, Siedlar M, Kania G, Błyszczuk P. Wnt3a and wnt5a transported by exosomes activate wnt signaling pathways in human cardiac fibroblasts. *Int J Mol Sci.* 2019;20:1436. doi: 10.3390/ijms20061436

174. Zou Y, Pan L, Shen Y, Wang X, Huang C, Wang H, Jin X, Yin C, Wang Y, Jia J, et al. Cardiac wnt5a and wnt11 promote fibrosis by the crosstalk of fzd5 and egfr signaling under pressure overload. *Cell Death Dis.* 2021;12:877. doi: 10.1038/s41419-021-04152-2

175. McGuire PJ. Mitochondrial dysfunction and the aging immune system. *Biology.* 2019;8:26. doi: 10.3390/biology8020026

176. Costa R, Peruzzo R, Bachmann M, Montà GD, Vicario M, Santinon G, Mattarei A, Moro E, Quintana-Cabrera R, Scorrano L, et al. Impaired mitochondrial atp production downregulates wnt signaling via er stress induction. *Cell Rep.* 2019;28:1949–1960.e6. doi: 10.1016/j. celrep.2019.07.050

177. Gay A, Towler DA. Wnt signaling in cardiovascular disease: opportunities and challenges. *Curr Opin Lipidol.* 2017;28:387–396. doi: 10.1097/MOL.0000000000000445

178. Albanese I, Khan K, Barratt B, Al-Kindi H, Schwertani A. Atherosclerotic calcification: wnt is the hint. *J Am Heart Assoc.* 2018;7: e007356. doi: 10.1161/JAHA.117.007356

179. Fulop T, Larbi A, Dupuis G, Le Page A, Frost EH, Cohen AA, Witkowski JM, Franceschi C. Immunosenescence and inflamm-aging as two sides of the same coin: friends or foes?. *Front Immunol.* 2017;8:1960. doi: 10.3389/fimmu.2017.01960

180. Baker DJ, Wijshake T, Tchkonia T, LeBrasseur NK, Childs BG, van de Sluis B, Kirkland JL, van Deursen JM. Clearance of p16ink4a-positive senescent cells delays ageing-associated disorders. *Nature.* 2011;479:232–236. doi: 10.1038/nature10600

181. Saul D, Kosinsky RL, Atkinson EJ, Doolittle ML, Zhang X, LeBrasseur NK, Pignolo RJ, Robbins PD, Niedernhofer LJ, Ikeno Y, Jurk D, Passos JF, Hickson LJ, Xue A, Monroe DG, Tchkonia T, Kirkland JL, Farr JN, Khosla S. A new gene set identifies senescent cells and predicts senescence-associated pathways across tissues. 2021:

182. Khosla S, Farr JN, Monroe DG. Cellular senescence and the skeleton: pathophysiology and therapeutic implications. *J Clin Invest.* 2022;132:e154888. doi: 10.1172/JCI154888

183. Pignolo RJ, Passos JF, Khosla S, Tchkonia T, Kirkland JL. Reducing senescent cell burden in aging and disease. *Trends Mol Med.* 2020;26:630–638. doi: 10.1016/j.molmed.2020.03.005

184. Lehmann M, Hu Q, Hu Y, Hafner K, Costa R, van den Berg A, Königshoff M. Chronic wnt/β-catenin signaling induces cellular senescence in lung epithelial cells. *Cell Signal.* 2020;70:109588. doi: 10.1016/j.cellsig.2020.109588

185. Ye X, Zerlanko B, Kennedy A, Banumathy G, Zhang R, Adams PD. Downregulation of wnt signaling is a trigger for formation of facultative heterochromatin and onset of cell senescence in primary human cells. *Mol Cell.* 2007;27:183–196. doi: 10.1016/j.molcel.2007.05.034

186. Lu Y, Wang Y, Weng T, Chen Z, Sun X, Wei J, Cai Z, Xiang M. Association between metformin use and coronary artery calcification in type 2 diabetic patients. *J Diabetes Res.* 2019;2019:9484717. doi: 10.1155/2019/9484717

187. Goldberg RB, Aroda VR, Bluemke DA, Barrett-Connor E, Budoff M, Crandall JP, Dabelea D, Horton ES, Mather KJ, Orchard TJ, et al; Diabetes Prevention Program Research GroupDiabetes Prevention Program Research Group. Effect of long-term metformin and lifestyle in the diabetes prevention program and its outcome study on coronary artery calcium. *Circulation.* 2017;136:52–64. doi: 10.1161/CIRCULATIONAHA.116.025483

188. Schinzari F, Tesauro M, Bertoli A, Valentini A, Veneziani A, Campia U, Cardillo C. Calcification biomarkers and vascular dysfunction in obesity and type 2 diabetes: influence of oral hypoglycemic agents. *Am J Physiol Endocrinol Metab.* 2019;317:E658–E666. doi: 10.1152/ajpendo.00204.2019

189. Cao X, Li H, Tao H, Wu N, Yu L, Zhang D, Lu X, Zhu J, Lu Z, Zhu Q. Metformin inhibits vascular calcification in female rat aortic smooth muscle cells via the ampk-enos-no pathway. *Endocrinology.* 2013;154:3680–3689. doi: 10.1210/en.2013-1002

190. Ma WQ, Sun XJ, Wang Y, Zhu Y, Han XQ, Liu NF. Restoring mitochondrial biogenesis with metformin attenuates beta-gp-induced phenotypic transformation of vsmcs into an osteogenic phenotype via inhibition of pdk4/ oxidative stress-mediated apoptosis. *Mol Cell Endocrinol.* 2019;479:39– 53. doi: 10.1016/j.mce.2018.08.012

191. Cui L, Li Z, Chang X, Cong G, Hao L. Quercetin attenuates vascular calcification by inhibiting oxidative stress and mitochondrial fission. *Vascul Pharmacol.* 2017;88:21–29. doi: 10.1016/j.vph.2016.11.006

192. Muller KH, Hayward R, Rajan R, Whitehead M, Cobb AM, Ahmad S, Sun M, Goldberga I, Li R, Bashtanova U, et al. Poly(adp-ribose) links the DNA damage response and biomineralization. *Cell Rep.* 2019;27:3124–3138.e13. doi: 10.1016/j.celrep.2019.05.038

193. Hayashi K, Nakamura S, Nishida W, Sobue K. Bone morphogenetic protein-induced msx1 and msx2 inhibit myocardin-dependent smooth muscle gene transcription. *Mol Cell Biol.* 2006;26:9456–9470. doi: 10.1128/MCB.00759-06

194. Tanaka T, Sato H, Doi H, Yoshida CA, Shimizu T, Matsui H, Yamazaki M, Akiyama H, Kawai-Kowase K, Iso T, et al. Runx2 represses myocardin-mediated differentiation and facilitates osteogenic conversion of vascular smooth muscle cells. *Mol Cell Biol.* 2008;28:1147–1160. doi: 10.1128/MCB.01771-07

195. Shirakabe K, Terasawa K, Miyama K, Shibuya H, Nishida E. Regulation of the activity of the transcription factor runx2 by two homeobox proteins, msx2 and dlx5. *Genes Cells.* 2001;6:851–856. doi: 10.1046/j. 1365-2443.2001.00466.x

196. Raaz U, Schellinger IN, Chernogubova E, Warnecke C, Kayama Y, Penov K, Hennigs JK, Salomons F, Eken S, Emrich FC, et al. Transcription factor runx2 promotes aortic fibrosis and stiffness in type 2 diabetes mellitus. *Circ Res.* 2015;117:513–524. doi: 10.1161/CIRCRESAHA. 115.306341

197. Schlotter F, Halu A, Goto S, Blaser MC, Body SC, Lee LH, Higashi H, DeLaughter DM, Hutcheson JD, Vyas P, et al. Spatiotemporal multi-omics mapping generates a molecular atlas of the aortic valve and reveals networks driving disease. *Circulation*. 2018;138:377–393. doi: 10.1161/ CIRCULATIONAHA.117.032291

198. Iqbal F, Lupieri A, Aikawa M, Aikawa E. Harnessing single-cell rna sequencing to better understand how diseased cells behave the way they do in cardiovascular disease. *Arterioscler Thromb Vasc Biol.* 2021;41: 585–600. doi: 10.1161/ATVBAHA.120.314776

199. Lilly B. We have contact: endothelial cell-smooth muscle cell interactions. *Physiology (Bethesda).* 2014;29:234–241. doi: 10.1152/ physiol.00047.2013

200. Zhang L, Yao J, Yao Y, Boström KI. Contributions of the endothelium to vascular calcification. *Front Cell Dev Biol.* 2021;9:620882. doi: 10.3389/fcell.2021.620882

201. Mao C, Ma Z, Jia Y, Li W, Xie N, Zhao G, Ma B, Yu F, Sun J, Zhou Y, et al. Nidogen-2 maintains the contractile phenotype of vascular smooth muscle cells and prevents neointima formation via bridging jagged1notch3 signaling. *Circulation.* 2021;144:1244–1261. doi: 10.1161/ CIRCULATIONAHA.120.053361

202. Juonala M, Magnussen CG, Venn A, Gall S, Kähönen M, Laitinen T, Taittonen L, Lehtimäki T, Jokinen E, Sun C, et al. Parental smoking in childhood and brachial artery flow-mediated dilatation in young adults: the cardiovascular risk in young finns study and the childhood determinants of adult health study. *Arterioscler Thromb Vasc Biol.* 2012;32:1024–1031. doi: 10.1161/ATVBAHA.111.243261

203. Zambrano E, Lomas-Soria C, Nathanielsz PW. Rodent studies of developmental programming and ageing mechanisms: special issue: In utero and early life programming of ageing and disease. *Eur J Clin Invest.* 2021;51:e13631. doi: 10.1111/eci.13631

204. Sutton NR, Bouis D, Mann KM, Rashid IM, McCubbrey AL, Hyman MC, Goldstein DR, Mei A, Pinsky DJ. Cd73 promotes age-dependent accretion of atherosclerosis. *Arterioscler Thromb Vasc Biol.* 2020;40:61–71. doi: 10.1161/ATVBAHA.119.313002

205. Ji H, Kwan AC, Chen MT, Ouyang D, Ebinger JE, Bell SP, Niiranen TJ, Bello NA, Cheng S. Sex differences in myocardial and vascular aging. *Circ Res.* 2022;130:566–577. doi: 10.1161/CIRCRESAHA.121.319902

206. Alsiraj Y, Thatcher SE, Blalock E, Fleenor B, Daugherty A, Cassis LA. Sex chromosome complement defines diffuse versus focal angiotensin ii-induced aortic pathology. *Arterioscler Thromb Vasc Biol.* 2018;38:143–153. doi: 10.1161/ATVBAHA.117.310035

Figure. Vascular aging and aging-accelerated vascular disease. Genetic and environmental factors induced endothelial cell dysfunction and vascular smooth muscle cell phenotypic modulation that leads to vascular remodeling and development of cardiovascular disease.

Table 1. Net Reclassification Index of Polygenic Risk Scores

Publication	Score description	Outcome	Group (ancestry)	No. of samples	Continuous NRI, %	Categorical NRI, %
Elliot et al*[94]	Lassosum	Incident CAD in UK Biobank	Events (EUR)	6272	15.4 (13.0 to 17.9)	4.4 (3.5 to 5.3)
			Nonevents (EUR)	346 388	15.8 (15.5 to 16.1)	−0.4 (−0.5 to −0.4)
			All (EUR)	352 600	31.2 (28.7 to 33.7)	4.0 (2.1 to 4.9)
			All (EUR)	4168		1.8 (−0.2 to 3.6)
			All (EUR)	2101		0.1 (−3.8 to 7.6)
Mars et al[82]	LDpred from external GWAS	Incident CHD in FIN-RISK	Events (FIN)	1209		0.9 (−0.02 to 2.0)
			Nonevents (FIN)	18 956		0.2 (−0.1 to 0.5)
			All (FIN)	20 165		1.1 (−0.1 to 2.2)
Hindy et al[95]	LDpred from Khera et al	Incident CAD in Malmö Diet and Cancer Study	Events (EUR)	815		17.3 (8.8 to 19.9)
			Nonevents (EUR)	4870		−0.9 (−1.8 to −0.2)
			All (EUR)			16.5 (7.6 to 18.2)
	LDpred from Khera et al	Incident CAD in UK Biobank	Events (EUR)	7708		9.1 (7.7 to 10.5)
			Nonevents (EUR)	317 295		−0.6 (−0.7 to −0.6)
			All (EUR)	325 003		8.5 (7.1 to 9.8)
Riveros-McKay*[96]	Novel PRS	Incident CAD in UKBiobank	Events	4122		5.97 (4.83 to 7.12)
			Nonevents	24 434		−0.09 (−0.26 to 0.08)
			All	186 451		5.88 (4.73,7.04)
Sun et al†[97]	metaPRS	Incident CVD in UKBiobank	Events (EUR)	5680	10.2 (7.2 to 13.2)	0.3 (−0.7 to 1.2)
			Nonevents (EUR)	300 974	12.6 (12.2 to 13.0)	2.2 (1.8 to 2.6)
Weale et al[98]	LDpred of custom GWAS summary statistics	Incident CVD combined across UKBiobank, MESA, ARIC	Events (EUR)	2096		2.7 (1.17 to 4.22)
			Events (AFR)	309		2.24 (0.39 to 4.08)
Lu et al[99]	Custom PRS of CAD and CAD-related traits in EAS and EUR	Incident CAD in China-PAR	Events (EAS)	840	15.7 (7.7 to 22.2)	3.2 (0.9 to 5.8)
			Nonevents (EAS)	32 859	10.1 (9.1 to 11.1)	0.3 (0.1 to 0.5)
			All (EAS)	33 699	25.8 (18.5 to 32.5)	3.5 (1.2 to 6.0)
Stienfeldt, et al‡[100]	6 PGS from PGS catalog	Incident MACE in UKBiobank	Nonevents (majority EUR)	371 909		0.05 (0.03 to 0.12)
			Events (majority EUR)	23 790		1.12 (0.62 to 1.54)
			All (majority EUR)	394 713		1.16 (0.66 to 1.59)

NRI for ASCVD-PCE vs PCE with polygenic score in several cohorts with various polygenic scores and primary outcomes used. Categorical NRI uses the 7.5% 10-year risk of ASCVD threshold unless otherwise noted. ACC/AHA indicates American College of Cardiology/American Heart Association; AFR, African genetic ancestry; ARIC, Atherosclerosis Risk in Communities study; ASCVD, atherosclerotic cardiovascular disease; BMS, Bristol Myers Squibb; CAD, coronary artery disease; CHD, coronary heart disease; CVD,

cardiovascular disease; EAS, East Asian genetic ancestry; EUR, European genetic ancestry; GWAS, genome-wide association studies; MACE, major adverse cardiac event; MESA, Multi-Ethnic Study of Atherosclerosis; NRI, net reclassification index; PCE, Pooled Cohorts Equation; PGS, polygenic scores; and SRA, sponsored research agreement.

* NRI multiplied by 100 as pseudo percentage with range −200 to 200.

† Comparison made between conventional risk factors alone and with polygenic score. Categorical NRI using <5%, 5% to 7.5%, and ≥7.5% 10-year risk thresholds according to 2019 ACC/AHA guidelines.

‡ Comparison made between a neural network CVD risk predictor with and without additional polygenic score predictors. Categorical NRI using 10% risk thresholds.

Table 2. Genetic Determinants of Vascular and Valvular Calcification

Genome-wide significant loci			
Calcific disorder	**Gene/locus (lead single nucleotide polymorphism)**	**Gene/locus description**	**Study**
Coronary artery calcification	**PHACTR1/EDN1** (rs9349379; chr 6)	Phosphatase and actin regulator 1; **EDN1**, a vasoconstrictor	O'Donnell et al,[105] Gupta et al[106]
	9p21 (rs1333049; chr 9)	CDKN2A/CDKN2B	O'Donnell et al[105]
	APOB (rs5742904; chr 2)	ApoB	Natarajan et al[107]
	APOE (rs7412; chr 19)	ApoE	Natarajan et al[107]
Abdominal aortic calcification	**HDAC9/TWIST1** (rs57301765; chr 7)	Histone deacetylase 9; modulator of osteogenic phenotype; promotes endothelial-to-mesenchymal transition twist family bHLH transcription factor 1	Malhotra et al,[108] Lecce et al,[109] Nurnberg et al[110]
Aortic valvular calcification	**LPA** (rs10455872; chr 6)	Lipoprotein a; causal role for Lp(a) in AV calcification	Thanassoulis et al,[111] Helgadottir et al[112]
	PALMD (rs7543130; chr 1)	Palmdelphin, also associated with congenital heart disease	Helgadottir et al[112]
	TEX41 (rs1830321; chr 2)	Testis expressed 41; also associated with congenital heart disease	Helgadottir et al[112]
Mitral valvular calcification	**IL1F9** (rs17659543; chr 2)	Interleukin 36 gamma; proinflammatory	Thanassoulis et al[111]
Mendelian disorders			
Calcific disorder	Gene(s)	Description	Study
GACI	**ENPP1** or **ABCC6**	Ectonucleotide pyrophosphatase/phosphodiesterase 1; ATP binding cassette subfamily C member 6; purine and pyrophosphate metabolism	Rutsch et al[113]
ACDC	**CD73** (aka **NT5E**)	Ecto-5'-nucleotidase or cluster of differentiation 73; purine metabolism	St. Hilaire et al[114]
Pseudoxanthoma elasticum	**ABCC6**	ATP binding cassette subfamily C member 6; purine and pyrophosphate metabolism	Jansen et al[115]